var title_f25_36_26176="CT findings in elevated ICP";
var content_f25_36_26176=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radiographic findings suggestive of elevated ICP",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 304px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Evidence of contusions with surrounding edema (top arrow), effacement of cisterns (middle arrow), and effacement of sulci (lowest arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_36_26176=[""].join("\n");
var outline_f25_36_26176=null;
var title_f25_36_26177="Endoscopic view of Zenkers diverticulum";
var content_f25_36_26177=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic view of Zenker's diverticulum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 394px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The esophageal lumen can be seen at the middle left side of the endoscopic image. A nasogastric tube has been placed. The lumen of the diverticulum can be observed at the lower right side of the image. The nasogastric tube will guide the endoscopist when cutting the diverticulum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Chris J J Mulder, MD, and Stijn J B van Weyenberg, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_36_26177=[""].join("\n");
var outline_f25_36_26177=null;
var title_f25_36_26178="Darier disease - nails";
var content_f25_36_26178=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Darier disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Distal notching and linear red and white bands are present on the nails.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_36_26178=[""].join("\n");
var outline_f25_36_26178=null;
var title_f25_36_26179="Heart transplantation";
var content_f25_36_26179=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Heart transplantation (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/36/26179/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/36/26179/contributors\" id=\"au4045\">",
"       Howard J Eisen, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/36/26179/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/36/26179/contributors\" id=\"se371\">",
"       Sharon A Hunt, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/36/26179/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/36/26179/contributors\" id=\"de1804\">",
"       Susan B Yeon, MD, JD, FACC",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?25/36/26179?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HEART TRANSPLANTATION OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Cardiac transplantation, also called heart transplantation, has evolved into the treatment of choice for many people with severe heart failure (HF) who have severe symptoms despite maximum medical therapy. Survival among cardiac transplant recipients has improved as a result of improvements in treatments that suppress the immune system and prevent infection.",
"    </p>",
"    <p>",
"     Unfortunately, the number of heart donors has reached a plateau despite an increasing number of potential recipients. More than 5000 cardiac transplants occur each year around the world, although it is estimated that up to 50,000 people are candidates for transplantation [",
"     <a class=\"abstract\" href=\"UTD.htm?25/36/26179/abstract/1\">",
"      1",
"     </a>",
"     ]. This critical organ shortage means that healthcare providers must strictly evaluate who should receive a heart transplant.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      REASONS FOR HEART TRANSPLANTATION",
"     </span>",
"    </p>",
"    <p>",
"     The American Society of Transplantation has published recommendations to guide healthcare providers about which patients should be considered for transplantation [",
"     <a class=\"abstract\" href=\"UTD.htm?25/36/26179/abstract/2\">",
"      2",
"     </a>",
"     ]. The major reason for cardiac transplantation is to improve survival. A second important reason is to enhance quality of life. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=see_link\">",
"      \"Indications and contraindications for cardiac transplantation\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Criteria for heart transplantation",
"     </span>",
"     &nbsp;&mdash;&nbsp;The primary task in selecting candidates for heart transplantation is the person's prognosis. There are many predictors of need for transplantation; one of the best predictors is the amount of oxygen required by the body, called VO2. This is measured as a person exercises on a treadmill. Poor heart function despite excellent medical therapy is another very important predictor of poor prognosis.",
"    </p>",
"    <p>",
"     The major reason for cardiac transplantation is to improve survival. Thus, being able to predict how a person will do after transplantation is the most important part of the patient selection process.",
"    </p>",
"    <p>",
"     The benefit of transplantation is clear if a person requires continuous intravenous (IV) medications in the hospital. In unhospitalized patients, the following requirements have been recommended for consideration for cardiac transplantation:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       A history of repeated hospitalizations for heart failure",
"      </li>",
"      <li>",
"       Need for ventricular assist device or artificial heart to support circulation",
"      </li>",
"      <li>",
"       Increasing types, dosages, and complexity of medications",
"      </li>",
"      <li>",
"       A reproducible VO2 of less than 14",
"       <span class=\"nowrap\">",
"        mL/kg",
"       </span>",
"       per minute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Patients are stratified into low, medium, and high risk of death without transplant. The final decision about listing a patient for transplant is determined by an established cardiac transplant center.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Deciding who gets a donor heart",
"     </span>",
"     &nbsp;&mdash;&nbsp;To ensure that donor hearts are distributed fairly, an organization known as UNOS (United Network for Organ Sharing) has created a system. This system spells out rules that consider time on the wait list, the severity of illness and the geographic distance between the donor hospital and the transplant center, measured in increasing 500 mile distances from the donor hospital. This system is regularly reviewed and revised with input from a wide variety of interested parties, including transplant professionals, recipients, and donor families.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      PRE-HEART TRANSPLANT EVALUATION",
"     </span>",
"    </p>",
"    <p>",
"     People who meet VO2",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     other heart requirements must also be evaluated for underlying medical problems, which may prevent a person from being eligible for transplantation. These include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Irreversible pulmonary hypertension",
"      </li>",
"      <li>",
"       Active infection",
"      </li>",
"      <li>",
"       Cancer",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Other factors will also be considered, including the person's age, the presence of diabetes or lung disease, and cigarette smoking or alcohol or substance abuse.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Pulmonary hypertension",
"     </span>",
"     &nbsp;&mdash;&nbsp;The major problem that prevents a person from being eligible for cardiac transplantation is irreversible pulmonary hypertension. People with irreversible pulmonary hypertension have an increased risk of right ventricular failure in the immediate postoperative period; during this time, the right ventricle in the donated heart must work especially hard to provide blood to the body.",
"    </p>",
"    <p>",
"     Fortunately, pulmonary hypertension can often be improved by using medications, including nitroprusside, nesiritide, dobutamine, milrinone, prostaglandin E1, prostacyclin, and inhaled nitric oxide. Milrinone therapy is highly effective, and is often used to determine if pulmonary hypertension is treatable. If pulmonary hypertension is controlled, a patient may be considered for transplantation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Infection and cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Two other reasons transplantation may not be possible are active infection and cancer of any kind. Both of these problems can be worsened by the medications given after heart transplantation. Even without preexisting cancer, the risk of developing cancer is increased following transplantation as a result of anti-rejection medications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Other concerns",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of other conditions that may affect a patient's ability to receive a cardiac transplantation, depending upon the individual situation.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       In the past, many programs routinely excluded people over the age of 55 to 60. However, carefully selected people in this age group (or older) have a survival rate comparable to that of younger patients. As a result, most centers now focus on the patient's \"physiologic\" age, which emphasizes the health of major organ systems (eg, kidneys, liver) and the number and severity of other underlying medical problems.",
"      </li>",
"      <li>",
"       Diabetes can interfere with wound healing and increase the risk of infections and vascular (blood vessel) complications. However, people with diabetes who do not have diabetes-associated complications in the kidney, retina, or nerves appear to do as well as people without diabetes who undergo heart transplantation. \" (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"        \"Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)\"",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Advanced lung disease can increase the risk of postoperative lung complications, including infection. In addition, recent pulmonary embolism (blood clot) with or without infarction (tissue death) are reasons to delay transplantation. Most centers treat a pulmonary embolism with anticoagulants (blood thinners) for six to eight weeks. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=see_link\">",
"        \"Patient information: Pulmonary embolism (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Other conditions that can limit a patient's ability to undergo cardiac transplantation include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Advanced liver (hepatic) disease. Cirrhosis, for example, can limit survival and increase the risk of death both before and after surgery. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=see_link\">",
"        \"Patient information: Cirrhosis (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Renal (kidney) insufficiency. The immunosuppressive drugs cyclosporine and tacrolimus can be toxic for the kidneys, especially if there is preexisting kidney disease. A combined kidney-heart transplantation may be offered to patients who could require transplantation of both organs within a few years. Over 100 cases of such combined transplantation from single donors have been reported. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"        \"Patient information: Chronic kidney disease (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       A number of other conditions increase the risk of complications, either due to the condition itself or the need for anti-rejection medications after transplantation. These conditions include: advanced peripheral vascular disease (claudication), severe obesity, advanced cardiac cirrhosis (liver disease caused by heart failure), active peptic ulcer disease, gallstones, and diverticulosis.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      PSYCHOLOGICAL EVALUATION",
"     </span>",
"    </p>",
"    <p>",
"     All heart transplantation candidates must have a complete psychological evaluation during the initial screening process. This helps to identify factors in a person's life that could cause difficulty during the waiting period, recovery, and postoperative period. A commitment to and understanding of the importance of anti-rejection medications is critical to the success of heart transplantation.",
"    </p>",
"    <p>",
"     Finally, all patients are screened for the use and abuse of alcohol and other recreational drugs (marijuana, cocaine, heroin). Anyone who abuses drugs or alcohol currently or in the recent past is not a good candidate for transplantation given the risk of post-transplant drug or alcohol abuse.",
"    </p>",
"    <p>",
"     Potential heart transplant recipients are advised stop smoking. Many centers will not list active smokers, and will check urine nicotine levels to ensure that the person has truly quit smoking. Recreational drugs, alcohol, and cigarette smoking are known to be harmful to the heart. Because the supply of donor hearts is limited and the demand is great, preference must be given to people who are likely to benefit the most and survive longest as a result of their transplant.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      OUTCOME AFTER FIRST HEART TRANSPLANT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Survival",
"     </span>",
"     &nbsp;&mdash;&nbsp;Approximately 85 to 90 percent of heart transplant patients are living one year after their surgery, with an annual death rate of approximately 4 percent thereafter. The three-year survival approaches 75 percent. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22775?source=see_link\">",
"      \"Prognosis after cardiac transplantation\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The outcome of patients undergoing heart transplantation for complex congenital (from birth) heart disease is similar to that of patients with other forms of heart disease. The one-year survival rate in people with congenital heart disease is 79 percent; at five years, the survival rate is 60 percent.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Prognosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of factors in both the recipient and the donor that are associated with poor outcomes after transplantation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Recipient factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Factors associated with an increased risk of death up to one year after transplantation include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Preoperative need for artificial breathing support (ventilator)",
"      </li>",
"      <li>",
"       If the heart transplantation is the second one for the recipient",
"      </li>",
"      <li>",
"       Heart conditions other than coronary artery disease or cardiomyopathy",
"      </li>",
"      <li>",
"       Preoperative need for heart function assistance with a ventricular assist device",
"      </li>",
"      <li>",
"       Being female",
"      </li>",
"      <li>",
"       Being underweight or obese",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Donor factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;A variety of donor factors affect the early outcomes:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A female donor is associated with increased one-year mortality.",
"      </li>",
"      <li>",
"       The age of the donor heart does not affect long-term survival, although transplant coronary artery disease is increased in hearts from donors over 40 years of age due to the presence of narrowing in the coronary arteries.",
"      </li>",
"      <li>",
"       Significant thickening of the left ventricle (left ventricular hypertrophy) in the donor heart is associated with poorer outcomes compared to a heart without thickening.",
"      </li>",
"      <li>",
"       Elevated blood levels of troponin I and T in the donor, which are markers of heart muscle damage, increase the risk of early heart failure.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Causes of death",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are four major causes of death after cardiac transplantation, which occur at different times:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Sudden (acute) rejection",
"      </li>",
"      <li>",
"       Infections other than cytomegalovirus (CMV)",
"      </li>",
"      <li>",
"       Artery disease in the transplanted heart vessels (allograft vasculopathy)",
"      </li>",
"      <li>",
"       Lymphoma and other malignancies",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Early mortality",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cardiac transplant recipients have an average of one to three episodes of rejection in the first year after transplantation. Between 50 and 80 percent of people experience at least one rejection episode. Acute rejection is most likely to occur in the first three to six months, with the incidence declining significantly after this time.",
"    </p>",
"    <p>",
"     In the first year, most deaths are due either to acute rejection (18 percent) or infections (22 percent). Infections often develop as a result of the anti-rejection medications and weakened immune system that are required to prevent rejection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Late mortality",
"     </span>",
"     &nbsp;&mdash;&nbsp;Rejection is less common after the first year, and by four to five years after transplantation, less than 10 percent of deaths are the result of rejection.",
"    </p>",
"    <p>",
"     However, development of rapidly progressing coronary artery disease in the arteries of the transplanted heart (called allograft vasculopathy), becomes one of the most common causes of death by five years. The number of fatal cancers increases over time as well. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/12/42184?source=see_link\">",
"      \"Prevention and treatment of cardiac allograft vasculopathy\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Infections remain a significant cause of death after the first year. These infections are the result of a weakened immune system, and can develop from common bacteria and viruses in the community or from uncommon infections.",
"    </p>",
"    <p>",
"     Posttransplant lymphoproliferative disease (PTLD) is a type of cancer that occurs in patients who use immunosuppressive medications. PTLD includes non-Hodgkin lymphoma (NHL). Most cases of PTLD occur in the first year after transplant. Among patients who develop lymphoma, the overall survival rates are between 25 to 35 percent at five years. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/60/27588?source=see_link\">",
"      \"Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"      \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      OUTCOME AFTER REPEAT HEART TRANSPLANTATION",
"     </span>",
"    </p>",
"    <p>",
"     Some people must consider a second heart transplant if rejection or allograft vasculopathy develops. Slightly more than 2 percent of heart transplant cases are retransplants every year.",
"    </p>",
"    <p>",
"     Survival after heart retransplantation is related to the time interval between the first transplant and the retransplant; a person is less likely to survive when this interval is short (ie, less than two years). When the interval between the first transplant and retransplantation is more than two years, the one-year survival is similar to that of a first transplantation (75 percent).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287378471\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H112840325\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/5/92?source=see_link\">",
"      Patient information: Heart transplant (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/32/7684?source=see_link\">",
"      Patient information: Systolic heart failure (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H112840340\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"      Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=see_link\">",
"      Patient information: Pulmonary embolism (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=see_link\">",
"      Patient information: Cirrhosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/60/27588?source=see_link\">",
"      Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28040?source=see_link\">",
"      Acute cardiac allograft rejection: Diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14441?source=see_link\">",
"      Acute cardiac allograft rejection: Treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23576?source=see_link\">",
"      Arrhythmias following cardiac transplantation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=see_link\">",
"      Indications and contraindications for cardiac transplantation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25862?source=see_link\">",
"      Left ventricular dysfunction after orthotopic cardiac transplantation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/25000?source=see_link\">",
"      Lipid abnormalities after cardiac transplantation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18585?source=see_link\">",
"      Natural history and diagnosis of cardiac allograft vasculopathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/12/42184?source=see_link\">",
"      Prevention and treatment of cardiac allograft vasculopathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22775?source=see_link\">",
"      Prognosis after cardiac transplantation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7783?source=see_link\">",
"      Rehabilitation after cardiac transplantation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/hearttransplantation.html\">",
"      www.nlm.nih.gov/medlineplus/hearttransplantation.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/health/dci/Diseases/ht/ht_whatis.html\">",
"      www.nhlbi.nih.gov/health/dci/Diseases/ht/ht_whatis.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.americanheart.org/\">",
"      www.americanheart.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       European Society of Cardiology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.heartfailurematters.org/\">",
"      www.heartfailurematters.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       United Network for Organ Sharing (UNOS)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.transplantliving.org/\">",
"      www.transplantliving.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?25/36/26179/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 29, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?25/36/26179?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26179/abstract/1\">",
"      Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report--2007. J Heart Lung Transplant 2007; 26:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26179/abstract/2\">",
"      Steinman TI, Becker BN, Frost AE, et al. Guidelines for the referral and management of patients eligible for solid organ transplantation. Transplantation 2001; 71:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26179/abstract/3\">",
"      Srivastava R, Keck BM, Bennett LE, Hosenpud JD. The results of cardiac retransplantation: an analysis of the Joint International Society for Heart and Lung Transplantation/United Network for Organ Sharing Thoracic Registry. Transplantation 2000; 70:606.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f25_36_26179=[""].join("\n");
var outline_f25_36_26179=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HEART TRANSPLANTATION OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           REASONS FOR HEART TRANSPLANTATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           PRE-HEART TRANSPLANT EVALUATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           PSYCHOLOGICAL EVALUATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           OUTCOME AFTER FIRST HEART TRANSPLANT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           OUTCOME AFTER REPEAT HEART TRANSPLANTATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f25_36_26180="Coal tar and salicylic acid: Patient drug information";
var content_f25_36_26180=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Coal tar and salicylic acid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/1/26642?source=see_link\">",
"     see \"Coal tar and salicylic acid: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F154060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tarsum&reg; [OTC];",
"     </li>",
"     <li>",
"      X-Seb T&reg; Pearl [OTC];",
"     </li>",
"     <li>",
"      X-Seb T&reg; Plus [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F154061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sebcur/T&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691803",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat dandruff.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat psoriasis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to control seborrheic dermatitis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701849",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to coal tar, salicylic acid, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may stain fingernails, hair, and skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect clothing and fabrics from staining.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698317",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Scalp irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705406",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Gel:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695291",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Leave it on your skin for as long as your doctor told you to. Lather and then wash it off.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705526",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shampoo:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696267",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wet hair and scalp.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on enough shampoo to make a lather.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695277",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lather well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695594",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse and put on again.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695591",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse and dry hair.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11475 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.244-E0F60D9195-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_36_26180=[""].join("\n");
var outline_f25_36_26180=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154060\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154061\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017530\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017529\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017534\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017535\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017537\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017532\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017533\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017538\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017539\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/1/26642?source=related_link\">",
"      Coal tar and salicylic acid: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_36_26181="Galsulfase (recombinant human N-acetylgalactosamine-4 sulfatase): Drug information";
var content_f25_36_26181=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Galsulfase (recombinant human N-acetylgalactosamine-4 sulfatase): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/59/5044?source=see_link\">",
"    see \"Galsulfase (recombinant human N-acetylgalactosamine-4 sulfatase): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11381?source=see_link\">",
"    see \"Galsulfase (recombinant human N-acetylgalactosamine-4 sulfatase): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F744563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Naglazyme&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F744567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Enzyme",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F744605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedicate with antihistamines with/without antipyretics 30-60 minutes prior to infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     MPS VI: I.V.: 1 mg/kg once weekly",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F744592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11381?source=see_link\">",
"      see \"Galsulfase (recombinant human N-acetylgalactosamine-4 sulfatase): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedicate with antihistamines with/without antipyretics 30-60 minutes prior to infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     MPS VI: Children &gt;5 years: I.V.: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F744597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naglazyme&reg;: 5 mg/5 mL (5 mL) [contains polysorbate 80; derived from or manufactured using Chinese hamster ovary cells]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F744565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F744593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Administer using infusion pump and PVC infusion set with in-line low protein-binding 0.2 micrometer filter. Pretreatment with antihistamines with or without antipyretics is recommended 30-60 minutes prior to infusion. Infuse a 250 mL solution at 6 mL/hour for the first hour. If well-tolerated, increase to 80 mL/hour for the remaining 3 hours. Doses prepared in 100 mL should also be infused over at least 4 hours. In case of infusion-related reactions, decrease infusion rate or temporarily discontinue. Infusion time can be extended up to 20 hours if infusion reactions occur. Discontinue immediately if severe reaction occurs. Patients requiring supplemental oxygen or CPAP during sleep should have these treatments readily available in case of infusion-related or antihistamine-induced reaction.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F744586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Stable in NS.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F744570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Replacement therapy in mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy Syndrome) for improvement of walking and stair-climbing capacity",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F744580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Percentages reported are from a placebo-controlled study (39 patients, 19 on galsulfase); also included are adverse effects noted during other clinical studies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain (16%), hypertension (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Pain (32%), chills (21%), malaise (11%), fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Rash (21%), angioedema, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (47%), gastroenteritis (11%), nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (42%), areflexia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Ocular: Conjunctivitis (21%), corneal opacification increased (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Otic: Ear pain (42%), hearing impairment (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Dyspnea (21%), pharyngitis (11%), nasal congestion (11%), laryngeal edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Antigalsulfase antibodies (98%), infusion reactions (56%), umbilical hernia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, bradycardia, bronchospasm, cyanosis, erythema, hypotension, hypoxia, membranous nephropathy, pallor, paresthesia, respiratory failure, shock, tachycardia, tachypnea, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F744574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     There are no contraindications listed within the manufacturer&rsquo;s approved labeling",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F744575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Severe hypersensitivity reactions, including anaphylactic reactions and anaphylactic shock have been reported during and within 24 hours after infusion; immediate treatment for hypersensitivity reactions should be available during administration. Discontinue treatment immediately if signs or symptoms occur; use caution with readministration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune-mediated reactions: Severe immune-mediated reactions (eg, membranous glomerulonephritis) have occurred; monitor patients closely and consider discontinuation of treatment if signs or symptoms occur; use caution with readministration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion reactions: Infusion-related reactions have been reported; may be sporadic and/or severe; reactions may occur as late as week 146 of treatment. Patients should be premedicated with antihistamines and/or antipyretics prior to infusion; evaluate airway prior to therapy (due to possible effects of antihistamine use). In case of reaction, decrease the rate of infusion, temporarily discontinue the infusion, and/or administer additional antipyretics/antihistamines and possibly corticosteroids. Discontinue treatment immediately if severe reaction occurs; use caution with readministration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute febrile/respiratory illness: Consider delaying treatment in patients with an acute febrile or respiratory illness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patients at risk for fluid overload: Use with caution in patients who are at risk of fluid overload (patients &lt;20 kg, underlying respiratory disease, or compromised cardiopulmonary function); may cause heart failure. Monitor patients closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleep apnea: Use with caution in patients with sleep apnea; antihistamine pretreatment may increase the risk of apneic episodes; apnea treatment options should be readily available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adults: Studies did not include patients &gt;29 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Preparation: Excess agitation of solution prior to or after dilution may denature galsulfase rendering it inactive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Registry: A Clinical Surveillance Program has been created to monitor therapeutic response, progression of disease and adverse effects during long-term treatment, as well as, effects on pregnant women, breast-feeding, and their offspring; patients should be encouraged to register. Registry information may be obtained at  file://www.naglazyme.com/en/clinical-resources/surveillance-program.aspx or by calling 800-983-4587.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F744571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F744572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Fetal harm was not reported in animal studies. There are no studies in pregnant women. Pregnant women are encouraged to enroll in the Clinical Surveillance Program.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F744573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F744604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Breast-feeding women are encouraged to enroll in the Clinical Surveillance Program.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Naglazyme Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (5 mL): $2074.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F744595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Monitor for infusion/hypersensitivity reactions. In clinical studies, tests of mobility and physical function were monitored at baseline and every 6 weeks.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Naglazyme (BE, CH, CZ, DE, DK, EE, ES, FR, GR, IE, IL, IT, NL, PT, SE, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F744587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Galsulfase is a recombinant form of N-acetylgalactosamine 4-sulfatase, produced in Chinese hamster cells. A deficiency of this enzyme leads to accumulation of the glycosaminoglycan dermatan sulfate in various tissues, causing progressive disease which includes decreased growth, skeletal deformities, upper airway obstruction, clouding of the cornea, heart disease, and coarse facial features. Replacement of this enzyme has been shown to improve mobility and physical function (measured by walking and stair-climbing).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F744589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Week 1: 56-323 mL/kg; Week 24: 59-2799 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Week 1: Median 9 minutes (range: 6-21 minutes); Week 24: Median 26 minutes (range: 8-40 minutes)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Giugliani R, Harmatz P, and Wraith JE, \"Management Guidelines for Mucopolysaccharidosis VI,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 120(2):405-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/36/26181/abstract-text/17671068/pubmed\" id=\"17671068\" target=\"_blank\">",
"        17671068",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harmatz P, Giugliani R, Schwartz IV, et al, \"Long-Term Follow-Up of Endurance and Safety Outcomes During Enzyme Replacement Therapy for Mucopolysaccharidosis VI: Final Results of Three Clinical Studies of Recombinant Human N-Acetylgalactosamine 4-Sulfatase,\"",
"      <i>",
"       Mol Genet Metab",
"      </i>",
"      , 2008, 94(4):469-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/36/26181/abstract-text/18502162/pubmed\" id=\"18502162\" target=\"_blank\">",
"        18502162",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harmatz P, Ketteridge D, Giugliani R, et al, \"Direct Comparison of Measures of Endurance, Mobility, and Joint Function During Enzyme-Replacement Therapy of Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): Results After 48 Weeks in a Phase 2 Open-Label Clinical Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2005, 115(6):e681-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/36/26181/abstract-text/15930196/pubmed\" id=\"15930196\" target=\"_blank\">",
"        15930196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harmatz P, Whitley CB, Waber L, et al, \"Enzyme Replacement Therapy in Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome),\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2004, 144:574-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/36/26181/abstract-text/15126989/pubmed\" id=\"15126989\" target=\"_blank\">",
"        15126989",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9007 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-3C5F28D7A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_36_26181=[""].join("\n");
var outline_f25_36_26181=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744563\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744567\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744605\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744592\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896334\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896335\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744597\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744565\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744593\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744586\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744570\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744580\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744574\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744575\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299385\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220567\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744571\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744572\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744573\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744604\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324122\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744595\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539957\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744587\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744589\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9007\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9007|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/59/5044?source=related_link\">",
"      Galsulfase (recombinant human N-acetylgalactosamine-4 sulfatase): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11381?source=related_link\">",
"      Galsulfase (recombinant human N-acetylgalactosamine-4 sulfatase): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_36_26182="Trimethoprim: Drug information";
var content_f25_36_26182=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trimethoprim: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/9/146?source=see_link\">",
"    see \"Trimethoprim: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/8/5255?source=see_link\">",
"    see \"Trimethoprim: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F231470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Primsol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Trimethoprim&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F231508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F231474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Pneumocystis jirovecii",
"      </i>",
"     </b>",
"     <b>",
"      pneumonia, mild-to-moderate (unlabeled use) (CDC, 2009):",
"     </b>",
"     Oral: 15 mg/kg/day in 3 divided doses in combination with dapsone",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Susceptible infections:",
"     </b>",
"     Oral: 100 mg every 12 hours or 200 mg every 24 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Urinary tract infection, uncomplicated (unlabeled duration):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Treatment:",
"     </i>",
"     100 mg every 12 hours for 3 days (Gupta, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Prophylaxis:",
"     </i>",
"     100 mg once daily (Kodner, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F231493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/8/5255?source=see_link\">",
"      see \"Trimethoprim: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Susceptible infections:",
"     </b>",
"     Children &ge;2 months: Oral: 4-6 mg/kg/day in divided doses every 12 hours (dosing for UTI in Schleiss, 2007);",
"     <b>",
"      Note:",
"     </b>",
"     AAP guidelines on treatment of UTI recommend 6-12 mg trimethoprim/kg/day (in combination with sulfamethoxazole) in 2 divided doses  (AAP, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute otitis media:",
"     </b>",
"     Children &ge;6 months: Oral: 10 mg/kg/day in divided doses every 12 hours for 10 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F231475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F231476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-30 mL/minute: Administer 50 mg every 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute: Not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderately dialyzable (20% to 50%)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F231446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primsol&reg;: 50 mg/5 mL (473 mL) [dye free, ethanol free; contains propylene glycol, sodium benzoate; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F231432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F231451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with milk or food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F231450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of urinary tract infections due to susceptible strains of",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      P. mirabilis",
"     </i>",
"     ,",
"     <i>",
"      K. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      Enterobacter",
"     </i>",
"     spp and coagulase-negative",
"     <i>",
"      Staphylococcus",
"     </i>",
"     including",
"     <i>",
"      S. saprophyticus",
"     </i>",
"     ; acute otitis media due to susceptible strains of",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     and",
"     <i>",
"      H. influenzae",
"     </i>",
"     in children",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F12822141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alternative agent for",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (in combination with dapsone)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F231506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Aseptic meningitis (rare), fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Maculopapular rash (3% to 7% at 200 mg/day; incidence higher with larger daily doses), erythema multiforme (rare), exfoliative dermatitis (rare), pruritus (common), phototoxic skin eruptions, Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia, hyponatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Epigastric distress, glossitis, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia, megaloblastic anemia, methemoglobinemia, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice (rare), liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN and creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F231454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to trimethoprim or any component of the formulation; megaloblastic anemia due to folate deficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F231436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patients with potential for folate deficiency: Use with caution in patients with potential folate deficiency (malnourished, chronic anticonvulsant therapy, or elderly).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F231504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (moderate), CYP2C9 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F231441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Trimethoprim may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amantadine: Trimethoprim may enhance the adverse/toxic effect of Amantadine. Specifically, the risk of myoclonus and/or delirium may be increased. Amantadine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Amantadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Trimethoprim may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Trimethoprim may decrease the metabolism of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: Trimethoprim may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): May increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Dapsone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Trimethoprim may enhance the adverse/toxic effect of Dapsone (Topical). More specifically, trimethoprim may increase the risk for hemolysis",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Trimethoprim may decrease the excretion of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Trimethoprim may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Trimethoprim may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamiVUDine: Trimethoprim may decrease the excretion of LamiVUDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leucovorin Calcium-Levoleucovorin: May diminish the therapeutic effect of Trimethoprim. Management: Avoid concurrent use of leucovorin or levoleucovorin with trimethoprim (plus sulfamethoxazole) for",
"     <i>",
"      Pneumocystis jiroveci",
"     </i>",
"     pneumonia.  If trimethoprim is used for another indication, monitor closely for reduced efficacy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Memantine: Trimethoprim may enhance the adverse/toxic effect of Memantine. Specifically, the risk of myoclonus and/or delirium may be increased. Memantine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Memantine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: Trimethoprim may enhance the myelosuppressive effect of Mercaptopurine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Trimethoprim may increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Trimethoprim may enhance the adverse/toxic effect of Methotrexate.  Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (e.g., bone marrow suppression).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Trimethoprim may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Trimethoprim may increase the serum concentration of PRALAtrexate. More specifically, trimethoprim may decrease excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum level and/or possible toxicity with concomitant use of trimethoprim. Monitor for decreased pralatrexate levels with discontinuation of trimethoprim.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: Trimethoprim may increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Trimethoprim may decrease the metabolism of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: Trimethoprim may enhance the hyperkalemic effect of Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: Trimethoprim may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of trimethoprim, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F231443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F231457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because adverse effects have been observed in animals, trimethoprim is classified pregnancy category C. Trimethoprim crosses the placenta and can be detected in the fetal serum and amniotic fluid. Due to trimethoprim&rsquo;s potential effect on folic acid metabolism, TMP should only be used during pregnancy if the benefit justifies the potential risk. The use of dihydrofolate reductase inhibitors, including trimethoprim, during pregnancy may increase the risk of congenital anomalies including cardiovascular defects, oral clefts, urinary tract anomalies, and neural tube defects. Folic acid supplementation may decrease this risk. The majority of studies evaluating the effects of trimethoprim administration in pregnancy have been conducted with sulfamethoxazole/trimethoprim. Trimethoprim in combination with sulfamethoxazole is used in pregnancy for various indications (see the sulfamethoxazole/trimethoprim monograph for details).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F231481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8774835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Trimethoprim is excreted in breast milk. The manufacturer recommends caution while using trimethoprim in a breast-feeding woman because trimethoprim may interfere with folic acid metabolism. Nondose-related effects could include modification of bowel flora. Also see the sulfamethoxazole/trimethoprim monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F231458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause folic acid deficiency, supplements may be needed. Should be taken with milk or food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F231456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Primsol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/5 mL (473 mL): $288.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Trimethoprim Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $68.40",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13493305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic CBC and serum potassium during long-term therapy",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F231447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: Peak: 5-15 mg/L; Trough: 2-8 mg/L",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abaprim (IT);",
"     </li>",
"     <li>",
"      Alprim (AU, SG);",
"     </li>",
"     <li>",
"      Catin (TW);",
"     </li>",
"     <li>",
"      Giprim (TW);",
"     </li>",
"     <li>",
"      Idotrim (SE);",
"     </li>",
"     <li>",
"      Infectotrimet (DE);",
"     </li>",
"     <li>",
"      l (IE);",
"     </li>",
"     <li>",
"      Monotrim (BF, BJ, CH, CI, ET, GH, GM, GN, IE, KE, LR, MA, ML, MR, MU, MW, NE, NG, NL, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Motrim (AT);",
"     </li>",
"     <li>",
"      Primosept (CH);",
"     </li>",
"     <li>",
"      Sinersul (HR);",
"     </li>",
"     <li>",
"      Solotrim (AT, IL);",
"     </li>",
"     <li>",
"      Sulotrim (HR);",
"     </li>",
"     <li>",
"      Tediprima (ES);",
"     </li>",
"     <li>",
"      Tobyprim (ID);",
"     </li>",
"     <li>",
"      Trentina (ES);",
"     </li>",
"     <li>",
"      Trimcort (TW);",
"     </li>",
"     <li>",
"      Trimesan (PL);",
"     </li>",
"     <li>",
"      Trimetin (FI);",
"     </li>",
"     <li>",
"      Trimetop (EE);",
"     </li>",
"     <li>",
"      Trimetoprim (NO);",
"     </li>",
"     <li>",
"      Trimopan (DK, GB);",
"     </li>",
"     <li>",
"      Triprim (AU, CZ, TW);",
"     </li>",
"     <li>",
"      Urotrim (HR);",
"     </li>",
"     <li>",
"      Utisept (TH);",
"     </li>",
"     <li>",
"      Wellcoprim (BE, FR, LU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F231435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits folic acid reduction to tetrahydrofolate, and thereby inhibits microbial growth",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F231453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Readily and extensive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely into body tissues and fluids (middle ear, prostate, bile, aqueous humor, CSF)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 42% to 46%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Partially hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 8-14 hours; prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60% to 80%) as unchanged drug",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/36/26182/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(4):1-207.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta K, Hooton TM, Naber KG, et al, &ldquo;International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(5):e103-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/36/26182/abstract-text/21292654/pubmed\" id=\"21292654\" target=\"_blank\">",
"        21292654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoppu K, Koskimies O, and Vilska J, &ldquo;Trimethoprim in the Treatment of Acute Urinary Tract Infections in Children,&rdquo;",
"      <i>",
"       Int J Clin Pharmacol Ther Toxicol",
"      </i>",
"      , 1988, 26(2):65-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/36/26182/abstract-text/3410587/pubmed\" id=\"3410587\" target=\"_blank\">",
"        3410587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoppu K, &ldquo;Age Differences in Trimethoprim Pharmacokinetics: Need for Revised Dosing in Children?&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1987, 41(3):336-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/36/26182/abstract-text/3816021/pubmed\" id=\"3816021\" target=\"_blank\">",
"        3816021",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kodner CM and Thomas Gupton EK, &ldquo;Recurrent Urinary Tract Infections in Women: Diagnosis and Management,&rdquo;",
"      <i>",
"       Am Fam Physician",
"      </i>",
"      ,  2010, 82(6):638-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/36/26182/abstract-text/20842992/pubmed\" id=\"20842992\" target=\"_blank\">",
"        20842992",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Practice Parameter: The Diagnosis, Treatment, and Evaluation of the Initial Urinary Tract Infection in Febrile Infants and Young Children. American Academy of Pediatrics, Committee on Quality Improvement, Subcommittee on Urinary Tract Infection,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1999, 103(4 Pt 1):843-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/36/26182/abstract-text/10103321/pubmed\" id=\"10103321\" target=\"_blank\">",
"        10103321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schleiss MR, &ldquo;Principles of Antibacterial Therapy,&rdquo;",
"      <i>",
"       Nelson Textbook of Pediatrics",
"      </i>",
"      , 18th ed, Kliegman RM, Behrman RE, Jenson HB, and Stanton BF, eds, Philadelphia, PA: WB Saunders Co, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Varoquaux O, Lajoie D, Gobert C, et al, &ldquo;Pharmacokinetics of the Trimethoprim-Sulfamethoxazole Combination in the Elderly,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1985, 20:575-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/36/26182/abstract-text/3879182/pubmed\" id=\"3879182\" target=\"_blank\">",
"        3879182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10024 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-07BE0D3610-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_36_26182=[""].join("\n");
var outline_f25_36_26182=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231470\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231471\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231508\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231474\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231493\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231475\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231476\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231446\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231432\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231451\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231450\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12822141\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231506\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231454\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231436\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231504\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231441\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231443\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231457\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231481\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774835\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231458\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231456\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13493305\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231447\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038854\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231435\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231453\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10024\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10024|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/9/146?source=related_link\">",
"      Trimethoprim: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/8/5255?source=related_link\">",
"      Trimethoprim: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_36_26183="Gene expr profile AML ALL";
var content_f25_36_26183=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Gene expression profiling in acute leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure illustrates the use of gene expression arrays (or profiles) for distinguishing between acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Genes most highly expressed in ALL and AML are shown in the left-hand and right-hand panels, respectively (ie, \"ALL genes\" and \"AML genes\", respectively). Expression levels of each of the individual genes greater than the mean are shown in red; those genes expressed below the mean are shown in blue. Each column (ie, top to bottom) corresponds to a specific gene, while each row (ie, left to right) corresponds to expression levels in a single sample. The top 11 samples were from patients with AML, while the remainder were from patients with ALL. Note that, while the genes as a group appear correlated with either AML or ALL, no single gene is uniformly expressed in either type of leukemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 1999; 286:531. Reprinted with permission from AAAS.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.sciencemag.org\">",
"      file://www.sciencemag.org",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_36_26183=[""].join("\n");
var outline_f25_36_26183=null;
var title_f25_36_26184="Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma";
var content_f25_36_26184=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/36/26184/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/36/26184/contributors\">",
"     Edwin P Hui, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/36/26184/contributors\">",
"     Anthony TC Chan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/36/26184/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/36/26184/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/36/26184/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/36/26184/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/36/26184/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/36/26184/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasopharyngeal carcinoma is the predominant tumor type arising in the nasopharynx, the narrow tubular passage behind the nasal cavity. It differs from other head and neck squamous cell carcinomas in epidemiology, histology, natural history, and response to treatment.",
"   </p>",
"   <p>",
"    This topic discusses the epidemiology, etiology, diagnosis, and staging of nasopharyngeal carcinoma. The pathology and treatment and of nasopharyngeal carcinoma is presented elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8250?source=see_link\">",
"       \"Treatment of early and locoregionally advanced nasopharyngeal carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16280?source=see_link\">",
"       \"Treatment of recurrent and metastatic nasopharyngeal carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=see_link&amp;anchor=H11#H11\">",
"       \"Pathology of head and neck neoplasms\", section on 'Nasopharyngeal carcinoma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide, there are 80,000 incident cases and 50,000 deaths annually [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/1\">",
"     1",
"    </a>",
"    ]. Nasopharyngeal carcinoma displays a distinct racial and geographic distribution, which is reflective of its multifactorial etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Geographic and ethnic distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of nasopharyngeal carcinoma demonstrates a marked geographical variation. In the United States and Western Europe, it is rare, with an incidence of 0.5 to 2 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In contrast, nasopharyngeal carcinoma is endemic in southern China, including Hong Kong, where the incidence may reach 25 cases per 100,000 per year. Intermediate risk regions include Southeast Asia, North Africa and the Middle East, and the Arctic. Populations that migrate from areas of high to low risk retain an elevated risk, although this risk typically diminishes in successive generations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sex and age distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of nasopharyngeal carcinoma is two- to threefold higher in males compared with females.",
"   </p>",
"   <p>",
"    In high-risk populations, the incidence peaks around 50 to 59 years of age and declines thereafter. There is also a minor incidence peak observed among adolescents and young adults in Southeast Asia, the Middle",
"    <span class=\"nowrap\">",
"     East/North",
"    </span>",
"    Africa, and the United States. In most low-risk populations, nasopharyngeal carcinoma incidence increases with increasing age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Secular trend",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasopharyngeal carcinoma incidence has declined over the past 30 years in many endemic areas, including Hong Kong, Singapore, and Taiwan [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The reasons for this decline are unclear, although they are generally attributed to lifestyle changes associated with the rapid economic development that occurred in these areas. As an example, there has been a decreased use of salted fish in feeding infants and reduced exposure to traditional preserved food. However, the declining incidence may also be due to population shifts as a result of altered immigration patterns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The geographic variation of nasopharyngeal carcinoma incidence suggests a multifactorial etiology. In endemic populations, risk appears to be due to an interaction of several factors: Epstein-Barr virus (EBV) infection, genetic predisposition, and environmental factors such as the high intake of preserved foods and smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. Furthermore, the increased incidence in younger adults in high and intermediate risk areas suggests that exposure to a common agent early in life is a critical factor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/2\">",
"     2",
"    </a>",
"    ]. In the United States and Europe, nasopharyngeal carcinoma is more commonly associated with alcohol and tobacco usage, which are classic risk factors for other head and neck tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several dietary practices in endemic areas are thought to contribute to the high incidence of nasopharyngeal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/2,8-10,13-16\">",
"     2,8-10,13-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cooking of salt-cured food, which releases volatile nitrosamines that are carried by steam and distributed over the nasopharyngeal mucosa.",
"     </li>",
"     <li>",
"      Early childhood exposure to salted fish, which was traditionally used for weaning.",
"     </li>",
"     <li>",
"      High consumption of preserved or fermented foods, including meats, eggs, fruits, and vegetables, which contain high levels of nitrosamines as well as bacterial mutagens, direct genotoxins, and EBV-reactivating substances.",
"     </li>",
"     <li>",
"      The use of Chinese medicinal herbs, which may contribute either by reactivating EBV or through a direct promoting effect on EBV-transformed cells.",
"     </li>",
"     <li>",
"      The consumption among the Maghrebian population from Tunisia, Algeria, and Morocco of rancid butter and sheep's fat, which contain butyric acid, a potential EBV activator and causative agent for nasopharyngeal carcinoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Epstein-Barr virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large body of evidence supports the role of EBV as a primary etiologic agent in the pathogenesis of nasopharyngeal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. This includes the detection of both EBV DNA and EBV gene expression in precursor lesions and tumor cells. Nasopharyngeal carcinoma cells express a specific subgroup of EBV latent proteins, including EBNA-1 and two integral membrane proteins, LMP-1 and LMP-2, along with the BamHI-A fragment of the EBV genome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Patients with nasopharyngeal carcinoma also demonstrate specific serologic responses to various gene products of EBV [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/18-20,23,24\">",
"     18-20,23,24",
"    </a>",
"    ]. One such aberrant serologic response associated with nasopharyngeal carcinoma is immunoglobulin A (IgA) antibodies directed against EBV viral capsid antigen",
"    <span class=\"nowrap\">",
"     (VCA/IgA).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=see_link\">",
"     \"Virology of Epstein-Barr virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Smoking has also been associated with nasopharyngeal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/11,25\">",
"     11,25",
"    </a>",
"    ]. Smoking has also been associated with EBV seropositivity and may be involved in the pathogenesis of nasopharyngeal carcinoma by causing EBV reactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This association of nasopharyngeal carcinoma with EBV infection has been exploited to develop noninvasive diagnostic tests. It is also being used experimentally to treat advanced disease. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Epstein-Barr virus testing'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16280?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of recurrent and metastatic nasopharyngeal carcinoma\", section on 'Immunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1308895689\">",
"    <span class=\"h2\">",
"     Human papilloma virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human papilloma virus (HPV) was detected in a small subset of carcinomas involving the nasopharynx, but many of these may represent extension from a primary cancer of the oropharynx. In one small series of western patients \"diagnosed\" with nasopharyngeal cancer, HPV was detected in 4 of 45 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/26\">",
"     26",
"    </a>",
"    ]. Of the three patients with HPV-positive carcinomas and available staging information, all were found to have extension into the oropharynx.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Heredity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic factors may influence the risk of nasopharyngeal carcinoma. One case control study, for example, suggested that having a first degree relative with nasopharyngeal carcinoma increased risk sevenfold [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/27\">",
"     27",
"    </a>",
"    ]. With evidence for clustering within families, some have recommended screening for first-degree relatives of patients with nasopharyngeal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Nasopharyngeal carcinoma has been associated with certain HLA haplotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. Nasopharyngeal carcinoma has also been associated with genetic polymorphisms, such as CYP2A6, which is a polymorphism of a nitrosamine metabolizing gene [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Molecular pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have identified critical genetic and epigenetic events in nasopharyngeal carcinoma. Copy number losses on chromosomes 1p, 3p, 9p, 9q, 11q, 13q, 14q and 16q and recurrent gains on chromosome 1q, 3q, 8q, 12p and 12q are frequently observed in nasopharyngeal carcinoma.",
"   </p>",
"   <p>",
"    Although alterations of the well-established tumor suppressor genes, such as TP53 and RB1, are relatively rare in nasopharyngeal carcinoma tumors, multiple genetic and epigenetic alterations in other tumor suppressor genes and oncogenes have been detected [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/35\">",
"     35",
"    </a>",
"    ]. As an example, the roles of several important tumor suppressor genes (eg, p16 and RASSF1A) and oncogenes (eg, CCND1) have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the molecular basis of nasopharyngeal carcinoma pathogenesis is still poorly understood, pathogenesis and development of nasopharyngeal carcinoma appears to follow a multistep process [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/37\">",
"     37",
"    </a>",
"    ]. In individuals from endemic regions, the nasopharyngeal carcinoma associated genotypes for various alleles, such as HLA and the polymorphic genes for carcinogen metabolism, detoxification and DNA repair, may predispose the nasopharyngeal epithelial cells to DNA damage. Chronic exposure to carcinogens such as nitrosamines may lead to increased DNA damage and the formation of multiple lesions in the nasopharynx with clonal genetic changes. Genetic and epigenetic changes interact with latent EBV infection to disrupt major cellular mechanisms and contribute to the initiation and progression of nasopharyngeal carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presenting complaints in patients with nasopharyngeal carcinoma are headache, caused by cranial nerve involvement, and a mass in the neck, due to cervical node metastases. The clinical triad of a neck mass, nasal obstruction with epistaxis, and serous otitis media occurs infrequently, although each of these symptoms occurs commonly.",
"   </p>",
"   <p>",
"    Nasopharyngeal carcinoma frequently originates from the pharyngeal recess, the fossa of Rosenmuller. Since this is a clinically occult site, patients may remain asymptomatic for a prolonged period. The majority of patients present with locally",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    regionally advanced disease because of this prolonged asymptomatic period or in some cases due to a missed diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary tumor may present as a smooth bulge in the mucosa, a discrete nodule with or without surface ulceration, or an infiltrative fungating mass. Erosion into the skull base is common with or without impairment of cranial nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/41\">",
"     41",
"    </a>",
"    ]. Cranial nerves III, V, VI, and VII are most commonly affected because of para-cavernous sinus tumor invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nasopharyngeal carcinoma has a tendency for early metastatic spread [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/40,42,45\">",
"     40,42,45",
"    </a>",
"    ]. Lymph node metastases are present at diagnosis in 75 to 90 percent of cases and are bilateral nodes in over 50 percent. Distant metastases are present at initial diagnosis in 5 to 11 percent of patients.",
"   </p>",
"   <p>",
"    The location and extent of lymph node metastases are predictive of distant metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. The most frequent sites of distant metastases are bone (75 percent), lung, liver, and distant nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/45\">",
"     45",
"    </a>",
"    ]. Multiple paraneoplastic syndromes, including neutrophilia, fever of unknown origin, hypertrophic osteoarthropathy, and dermatomyositis can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/45,49\">",
"     45,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasopharyngeal carcinoma arises from the epithelial lining of the nasopharynx.",
"   </p>",
"   <p>",
"    The World Health Organization (WHO) classifies nasopharyngeal carcinoma into the following histopathologic types [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Keratinizing squamous cell carcinoma (WHO Type I): The sporadic form of nasopharyngeal carcinoma most commonly is the keratinizing subtype (WHO Type I).",
"     </li>",
"     <li>",
"      Nonkeratinizing carcinoma:",
"      <strong>",
"      </strong>",
"      This is subdivided into the differentiated (Type II) and undifferentiated (Type III) forms.",
"      <strong>",
"      </strong>",
"      The endemic form of nasopharyngeal carcinoma is commonly the undifferentiated, nonkeratinizing subtype. This is strongly associated with EBV and has a more favorable prognosis than other types. There is preliminary evidence that human papillomavirus (HPV) infection may be involved in EBV-negative nasopharyngeal carcinoma in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/51,52\">",
"       51,52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Basaloid squamous cell carcinoma: Basaloid squamous cell carcinoma was added to the WHO classification of head and neck tumors in 2005. There are few reported cases, which have been notable for an aggressive clinical course and poor survival [",
"      <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In North America, the relative frequencies of the different histologic subtypes are 25 percent keratinizing, 12 percent differentiated, and 63 percent undifferentiated. In contrast, the histological distribution among southern Chinese patients is 2 percent keratinizing, 3 percent differentiated, and 95 percent undifferentiated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=see_link\">",
"     \"Pathology of head and neck neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasopharyngeal carcinoma is clinically staged according to the International Union Against Cancer (UICC) and American Joint Committee on Cancer (AJCC) tumor node metastasis (TNM) system (",
"    <a class=\"graphic graphic_table graphicRef57392 \" href=\"UTD.htm?34/8/34957\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/55\">",
"     55",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     UICC/AJCC",
"    </span>",
"    TNM staging system, first published in 1997 and most recently revised in 2010, incorporates key features of the older Ho staging system [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The current TNM staging system classifies nodal stage according to size and lymph node location, whether above (N1 or N2) or within the supraclavicular fossa (N3). The supraclavicular fossa is a triangular zone defined by the superior margin of the sternal end of the clavicle, the superior margin of the lateral end of the clavicle, and the point where the neck meets the shoulder [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive diagnosis is made by endoscopically-guided biopsy of the primary tumor or biopsy of other masses or metastases. Routine evaluation should include history and physical examination, including the cranial nerves, complete blood counts, and serum biochemistry, including liver function tests and alkaline phosphatase. Other studies should include chest radiograph, nasopharyngoscopy, and computed tomography (CT) or magnetic resonance imaging (MRI) of the nasopharynx, skull base, and neck.",
"   </p>",
"   <p>",
"    MRI, if available, is preferred over CT. MRI appears to be superior for the identification of tumor invasion into soft tissue and bony structures, pharyngobasilar fascia obliteration, invasion into the sinus of Morgagni, skull base invasion, and lymph node metastases in the carotid and retropharyngeal spaces [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with clinical or biochemical evidence of distant metastases or otherwise considered at high risk for distant metastases (advanced nodal stage, N3), additional imaging with bone scan, CT of chest and upper abdomen,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    positron emission tomography (PET) or integrated PET-CT imaging may be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/47,56-58\">",
"     47,56-58",
"    </a>",
"    ]. Because of its superiority ability to detect lymph node and bone metastases, we suggest PET scanning, if available [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=see_link\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest obtaining pretreatment plasma EBV DNA levels for its prognostic contribution. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Epstein-Barr virus testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EPSTEIN-BARR VIRUS TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The strong etiologic link between EBV infection and nasopharyngeal carcinoma is supported by the abnormal anti-EBV antibody profiles, increased circulating EBV DNA levels, and distinct EBV gene expression in tumor cells. Various indicators of EBV infection have been investigated as an alternative to histopathologic diagnosis of nasopharyngeal carcinoma, as a method of noninvasive screening, and for monitoring for disease recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the high rates of nasopharyngeal carcinoma in specific geographic regions and among certain families and the high cure rate for early stage nasopharyngeal carcinoma, screening of high-risk populations has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/61-67\">",
"     61-67",
"    </a>",
"    ]. Various noninvasive methods of nasopharyngeal carcinoma detection have been studied; these include EBV-specific antibody-based assays, measurement of circulating EBV DNA levels, and EBV DNA and BARF1 oncogene mRNA detection from nasopharyngeal brushings.",
"   </p>",
"   <p>",
"    In patients with nasopharyngeal carcinoma, the characteristic anti-EBV serologic profile consists of a sustained rise in antibodies to viral capsid antigen (VCA) and early antigen (EA) IgA [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/45\">",
"     45",
"    </a>",
"    ]. In southern China, where nasopharyngeal carcinoma is endemic, EBV serology, ie, serum",
"    <span class=\"nowrap\">",
"     VCA/IgA",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     IgA/EA",
"    </span>",
"    antibody titers, has been used for population-based screening [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. However, EBV-specific serologic screening has limited specificity for nasopharyngeal carcinoma and an elevated titer may proceed a diagnosis of nasopharyngeal carcinoma for a period of up to ten years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Quantitation of circulating EBV DNA has also been studied as a method for nasopharyngeal carcinoma screening, and a large prospective study is ongoing to investigate the use of plasma EBV DNA in primary screening of nasopharyngeal carcinoma in an endemic area [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/64,68,69\">",
"     64,68,69",
"    </a>",
"    ]. The sensitivity and specificity of using circulating EBV DNA for the detection of nasopharyngeal carcinoma, with real-time polymerase chain reaction analysis (PCR), is 96 and 93 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/69\">",
"     69",
"    </a>",
"    ]. The sensitivity is lower when whole blood rather than plasma DNA is used [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A promising strategy for screening is the use of a confirmatory noninvasive test after positive serologic results. In one study, the combination of serum",
"    <span class=\"nowrap\">",
"     VCA/IgA",
"    </span>",
"    antibody and circulating EBV DNA had an overall sensitivity (positive result by either marker) of 99 percent, and EBV DNA identified three-fourths of the false-positive",
"    <span class=\"nowrap\">",
"     VCA/IgA",
"    </span>",
"    cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/65\">",
"     65",
"    </a>",
"    ]. These results suggest that an IgA VCA-based screening protocol augmented by the selective application of EBV DNA could improve screening accuracy with only a moderate increase in cost.",
"   </p>",
"   <p>",
"    Others have investigated the measurement of EBV DNA load combined with detection of BamHI-A rightward frame 1 (BARF1) mRNA detection in NP brushing samples [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/71\">",
"     71",
"    </a>",
"    ]. BARF1 is a viral oncogene that is exclusively expressed in EBV-positive carcinoma (ie, nasopharyngeal carcinoma and EBV-positive gastric carcinomas) and is virtually absent from EBV-associated lymphoma. With relatively good sensitivity and specificity, this method may also prove to be useful for confirmatory testing.",
"   </p>",
"   <p>",
"    Although screening for early detection is offered to first-degree relatives with nasopharyngeal carcinoma by a few oncology centers in Southern China, routine screening has not become a standard practice in other locations, and the utility of this approach continues to be debated. The combination of IgA VCA and plasma EBV DNA appears to be the most promising for screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not currently a routine component in the evaluation of nasopharyngeal carcinoma, pretreatment plasma EBV DNA levels have been correlated with outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/72-75\">",
"     72-75",
"    </a>",
"    ]. We suggest obtaining pretreatment plasma EBV DNA levels as part of the diagnostic and staging evaluation for its prognostic contribution. However, there is no consensus on which EBV DNA level to use as a cutoff; pretreatment levels of 1500 and 4000 have been used [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/72,74,75\">",
"     72,74,75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8250?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of early and locoregionally advanced nasopharyngeal carcinoma\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Monitoring for treatment response and recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring of posttreatment plasma EBV DNA levels may also have a role in evaluating treatment response and detecting recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/72\">",
"     72",
"    </a>",
"    ]. The sensitivity of EBV DNA in the detection of local recurrence after radiotherapy (tumors regrowing from an irradiated site) is much lower than that from a radiation-naive site [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26184/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8250?source=see_link\">",
"     \"Treatment of early and locoregionally advanced nasopharyngeal carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasopharyngeal carcinoma is an epithelial neoplasm arising in the nasopharynx.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although, nasopharyngeal carcinoma is rare in most parts of the world, it is endemic in southern China, southeast Asia, north Africa, and the Artic, where undifferentiated, nonkeratinizing squamous cell carcinoma is the predominant histology. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Histology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major etiological factors for endemic nasopharyngeal carcinoma are genetic susceptibility, early-age exposure to chemical carcinogens, and Epstein-Barr virus (EBV) infection. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the initial diagnostic evaluation of nasopharyngeal carcinoma, we suggest endoscopically guided biopsy of the primary tumor and magnetic resonance imaging (MRI) of the nasopharynx, skull base, and neck for assessing locoregional disease extent. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with advanced nodal stage (N3) or clinical or biochemical evidence of distant metastases, we suggest additional imaging with positron emission tomography (PET) or integrated PET-CT imaging, if available. Otherwise, bone scan and CT of the chest and abdomen may be obtained. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest obtaining pretreatment plasma EBV DNA levels for their prognostic significance. There is emerging evidence supporting serial measurement of plasma EBV DNA levels to assess treatment response or monitor for recurrence. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8250?source=see_link\">",
"       \"Treatment of early and locoregionally advanced nasopharyngeal carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/1\">",
"      Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/2\">",
"      Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15:1765.",
"     </a>",
"    </li>",
"    <li>",
"     Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and Genetics of Head and Neck Tumours. In: World Health Organization Classification of Tumors, IARC Press, Lyon 2005.",
"    </li>",
"    <li>",
"     Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. In: IARC CancerBase, 5, IARC Press, Lyon 2005. Vol 2.0.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/5\">",
"      Lee AW, Foo W, Mang O, et al. Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980-99): an encouraging reduction in both incidence and mortality. Int J Cancer 2003; 103:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/6\">",
"      Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/7\">",
"      Hsu C, Shen YC, Cheng CC, et al. Difference in the incidence trend of nasopharyngeal and oropharyngeal carcinomas in Taiwan: implication from age-period-cohort analysis. Cancer Epidemiol Biomarkers Prev 2006; 15:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/8\">",
"      Yuan JM, Wang XL, Xiang YB, et al. Preserved foods in relation to risk of nasopharyngeal carcinoma in Shanghai, China. Int J Cancer 2000; 85:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/9\">",
"      Farrow DC, Vaughan TL, Berwick M, et al. Diet and nasopharyngeal cancer in a low-risk population. Int J Cancer 1998; 78:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/10\">",
"      Liebowitz D. Nasopharyngeal carcinoma: the Epstein-Barr virus association. Semin Oncol 1994; 21:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/11\">",
"      Xu F, Xiong D, Xu Y, et al. An Epidemiological and Molecular Study of the Relationship. J Natl Cancer Inst.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/12\">",
"      Vaughan TL, Shapiro JA, Burt RD, et al. Nasopharyngeal cancer in a low-risk population: defining risk factors by histological type. Cancer Epidemiol Biomarkers Prev 1996; 5:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/13\">",
"      Hildesheim A, West S, DeVeyra E, et al. Herbal medicine use, Epstein-Barr virus, and risk of nasopharyngeal carcinoma. Cancer Res 1992; 52:3048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/14\">",
"      Zeng Y, Zhong JM, Ye SQ, et al. Screening of Epstein-Barr virus early antigen expression inducers from Chinese medicinal herbs and plants. Biomed Environ Sci 1994; 7:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/15\">",
"      Feng BJ, Jalbout M, Ayoub WB, et al. Dietary risk factors for nasopharyngeal carcinoma in Maghrebian countries. Int J Cancer 2007; 121:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/16\">",
"      Gallicchio L, Matanoski G, Tao XG, et al. Adulthood consumption of preserved and nonpreserved vegetables and the risk of nasopharyngeal carcinoma: a systematic review. Int J Cancer 2006; 119:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/17\">",
"      Atula S, Auvinen E, Grenman R, Syrj&auml;nen S. Human papillomavirus and Epstein-Barr virus in epithelial carcinomas of the head and neck region. Anticancer Res 1997; 17:4427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/18\">",
"      Pathmanathan R, Prasad U, Sadler R, et al. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995; 333:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/19\">",
"      Chien YC, Chen JY, Liu MY, et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 2001; 345:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/20\">",
"      Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/21\">",
"      Brooks L, Yao QY, Rickinson AB, Young LS. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992; 66:2689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/22\">",
"      Busson P, McCoy R, Sadler R, et al. Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J Virol 1992; 66:3257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/23\">",
"      Tune CE, Liavaag PG, Freeman JL, et al. Nasopharyngeal brush biopsies and detection of nasopharyngeal cancer in a high-risk population. J Natl Cancer Inst 1999; 91:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/24\">",
"      Ji MF, Wang DK, Yu YL, et al. Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br J Cancer 2007; 96:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/25\">",
"      Hsu WL, Chen JY, Chien YC, et al. Independent effect of EBV and cigarette smoking on nasopharyngeal carcinoma: a 20-year follow-up study on 9,622 males without family history in Taiwan. Cancer Epidemiol Biomarkers Prev 2009; 18:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/26\">",
"      Singhi AD, Califano J, Westra WH. High-risk human papillomavirus in nasopharyngeal carcinoma. Head Neck 2012; 34:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/27\">",
"      Ung A, Chen CJ, Levine PH, et al. Familial and sporadic cases of nasopharyngeal carcinoma in Taiwan. Anticancer Res 1999; 19:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/28\">",
"      Loh KS, Goh BC, Lu J, et al. Familial nasopharyngeal carcinoma in a cohort of 200 patients. Arch Otolaryngol Head Neck Surg 2006; 132:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/29\">",
"      Hildesheim A, Apple RJ, Chen CJ, et al. Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 2002; 94:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/30\">",
"      Lu CC, Chen JC, Jin YT, et al. Genetic susceptibility to nasopharyngeal carcinoma within the HLA-A locus in Taiwanese. Int J Cancer 2003; 103:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/31\">",
"      Feng BJ, Huang W, Shugart YY, et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet 2002; 31:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/32\">",
"      Hu SP, Day NE, Li DR, et al. Further evidence for an HLA-related recessive mutation in nasopharyngeal carcinoma among the Chinese. Br J Cancer 2005; 92:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/33\">",
"      Tiwawech D, Srivatanakul P, Karalak A, Ishida T. Cytochrome P450 2A6 polymorphism in nasopharyngeal carcinoma. Cancer Lett 2006; 241:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/34\">",
"      Cao Y, Miao XP, Huang MY, et al. Polymorphisms of XRCC1 genes and risk of nasopharyngeal carcinoma in the Cantonese population. BMC Cancer 2006; 6:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/35\">",
"      Tao Q, Chan AT. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 2007; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/36\">",
"      Chan AT, Teo PM, Huang DP. Pathogenesis and treatment of nasopharyngeal carcinoma. Semin Oncol 2004; 31:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/37\">",
"      Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell 2004; 5:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/38\">",
"      Leong JL, Fong KW, Low WK. Factors contributing to delayed diagnosis in nasopharyngeal carcinoma. J Laryngol Otol 1999; 113:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/39\">",
"      Fandi A, Altun M, Azli N, et al. Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol 1994; 21:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/40\">",
"      Hsu MM, Tu SM. Nasopharyngeal carcinoma in Taiwan. Clinical manifestations and results of therapy. Cancer 1983; 52:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/41\">",
"      King AD, Lam WW, Leung SF, et al. MRI of local disease in nasopharyngeal carcinoma: tumour extent vs tumour stage. Br J Radiol 1999; 72:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/42\">",
"      Vokes EE, Liebowitz DN, Weichselbaum RR. Nasopharyngeal carcinoma. Lancet 1997; 350:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/43\">",
"      Aiken RD. Neurologic complications of head and neck cancers. Semin Oncol 2006; 33:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/44\">",
"      Neel HB 3rd. A prospective evaluation of patients with nasopharyngeal carcinoma: an overview. J Otolaryngol 1986; 15:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/45\">",
"      Altun M, Fandi A, Dupuis O, et al. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys 1995; 32:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/46\">",
"      Ho JH. An epidemiologic and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1978; 4:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/47\">",
"      Sakata K, Hareyama M, Tamakawa M, et al. Prognostic factors of nasopharynx tumors investigated by MR imaging and the value of MR imaging in the newly published TNM staging. Int J Radiat Oncol Biol Phys 1999; 43:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/48\">",
"      Liao XB, Mao YP, Liu LZ, et al. How does magnetic resonance imaging influence staging according to AJCC staging system for nasopharyngeal carcinoma compared with computed tomography? Int J Radiat Oncol Biol Phys 2008; 72:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/49\">",
"      Cvitkovic E, Bachouchi M, Boussen H, et al. Leukemoid reaction, bone marrow invasion, fever of unknown origin, and metastatic pattern in the natural history of advanced undifferentiated carcinoma of nasopharyngeal type: a review of 255 consecutive cases. J Clin Oncol 1993; 11:2434.",
"     </a>",
"    </li>",
"    <li>",
"     Pathology and genetics of head and neck tumors. In: World Health Organization Classification of Tumours, Barnes L, Eveson JW, Reichart P, Sidransky D (Eds), IARC Press, Lyon 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/51\">",
"      Maxwell JH, Kumar B, Feng FY, et al. HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans. Head Neck 2010; 32:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/52\">",
"      Punwaney R, Brandwein MS, Zhang DY, et al. Human papillomavirus may be common within nasopharyngeal carcinoma of Caucasian Americans: investigation of Epstein-Barr virus and human papillomavirus in eastern and western nasopharyngeal carcinoma using ligation-dependent polymerase chain reaction. Head Neck 1999; 21:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/53\">",
"      M&uuml;ller E, Beleites E. The basaloid squamous cell carcinoma of the nasopharynx. Rhinology 2000; 38:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/54\">",
"      Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005; 365:2041.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/56\">",
"      Caglar M, Ceylan E, Ozyar E. Frequency of skeletal metastases in nasopharyngeal carcinoma after initiation of therapy: should bone scans be used for follow-up? Nucl Med Commun 2003; 24:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/57\">",
"      Lee AW, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992; 23:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/58\">",
"      Chiesa F, De Paoli F. Distant metastases from nasopharyngeal cancer. ORL J Otorhinolaryngol Relat Spec 2001; 63:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/59\">",
"      Chang JT, Chan SC, Yen TC, et al. Nasopharyngeal carcinoma staging by (18)F-fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 2005; 62:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/60\">",
"      Liu FY, Chang JT, Wang HM, et al. [18F]fluorodeoxyglucose positron emission tomography is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol 2006; 24:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/61\">",
"      Chua DT, Ji M, Zong Y, Chan K. Screening of nasopharyngeal carcinoma by serology and nasopharyngoscopy and treatment outcome in endemic region. J Clin Oncol 2009; 27:308s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/62\">",
"      Zong YS, Sham JS, Ng MH, et al. Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer 1992; 69:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/63\">",
"      Zeng Y, Zhang LG, Wu YC, et al. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer 1985; 36:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/64\">",
"      Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999; 59:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/65\">",
"      Leung SF, Tam JS, Chan AT, et al. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem 2004; 50:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/66\">",
"      Ng WT, Yau TK, Yung RW, et al. Screening for family members of patients with nasopharyngeal carcinoma. Int J Cancer 2005; 113:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/67\">",
"      Cho WC. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer 2007; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/68\">",
"      Stevens SJ, Verkuijlen SA, Hariwiyanto B, et al. Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. J Clin Microbiol 2005; 43:3066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/69\">",
"      Chan KC, Lo YM. Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/70\">",
"      Lit LC, Chan KC, Leung SF, et al. Distribution of cell-free and cell-associated Epstein-Barr virus (EBV) DNA in the blood of patients with nasopharyngeal carcinoma and EBV-associated lymphoma. Clin Chem 2004; 50:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/71\">",
"      Stevens SJ, Verkuijlen SA, Hariwiyanto B, et al. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA. Int J Cancer 2006; 119:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/72\">",
"      Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006; 24:5414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/73\">",
"      Liu FF, Frappier L, Kim J, et al. East-West Symposium on nasopharyngeal cancer. Int J Radiat Oncol Biol Phys 2007; 67:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/74\">",
"      Chan AT, Lo YM, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002; 94:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/75\">",
"      Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350:2461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26184/abstract/76\">",
"      Leung SF, Lo YM, Chan AT, et al. Disparity of sensitivities in detection of radiation-na&iuml;ve and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2. Clin Cancer Res 2003; 9:3431.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3404 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-0CE6B713CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_36_26184=[""].join("\n");
var outline_f25_36_26184=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Geographic and ethnic distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sex and age distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Secular trend",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Epstein-Barr virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1308895689\">",
"      Human papilloma virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Heredity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EPSTEIN-BARR VIRUS TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Monitoring for treatment response and recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3404\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3404|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/8/34957\" title=\"table 1\">",
"      TNM stage nasopharynx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=related_link\">",
"      Pathology of head and neck neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8250?source=related_link\">",
"      Treatment of early and locoregionally advanced nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16280?source=related_link\">",
"      Treatment of recurrent and metastatic nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=related_link\">",
"      Virology of Epstein-Barr virus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_36_26185="Osteogenesis imperfecta: Management and prognosis";
var content_f25_36_26185=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Osteogenesis imperfecta: Management and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/36/26185/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/36/26185/contributors\">",
"     John F Beary, III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/36/26185/contributors\">",
"     Arkadi A Chines, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/36/26185/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/36/26185/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/36/26185/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/36/26185/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/36/26185/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteogenesis imperfecta (OI) is an inherited connective tissue disorder with many phenotypic presentations. It is often called \"brittle bone disease.\" Severely affected patients suffer multiple fractures with minimal or no trauma, and infants with the worst form of OI die in the perinatal period. Mild forms of OI may manifest with only premature osteoporosis or severe postmenopausal bone mineral loss.",
"   </p>",
"   <p>",
"    The goals of therapy for patients with OI are to reduce fracture rates, prevent long-bone deformities and scoliosis, minimize chronic pain, and to maximize mobility and other functional capabilities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Patients with OI should be referred for evaluation by specialists in genetics and, if clinically indicated, orthopedics with expertise in treating OI at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/4\">",
"     4",
"    </a>",
"    ]. Treatment requires a coordinated multidisciplinary team approach and consists of physical therapy, surgical interventions, medications, and, in some cases, experimental therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Patients with OI need additional health supervision from their primary care providers and monitoring for potential complications.",
"   </p>",
"   <p>",
"    The management and prognosis of osteogenesis imperfecta are presented here. The pathogenesis, clinical features, diagnosis, and differential diagnosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=see_link\">",
"     \"Osteogenesis imperfecta: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13635515\">",
"    <span class=\"h1\">",
"     BISPHOSPHONATE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates are the mainstay of pharmacologic fracture-prevention therapy for most forms of OI (except for type VI (",
"    <a class=\"graphic graphic_table graphicRef78737 \" href=\"UTD.htm?20/3/20541\">",
"     table 1",
"    </a>",
"    ) in which bone mineralization is defective), although none are approved specifically for use in either children or adults with OI. We suggest treatment with intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    for patients with all forms of OI, except type VI, in whom clinical benefits are likely to outweigh potential long-term risks (ie, those with long-bone deformities, vertebral compression fractures, and &ge;3 fractures per year). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=see_link&amp;anchor=H5114631#H5114631\">",
"     \"Osteogenesis imperfecta: Clinical features and diagnosis\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bisphosphonates are stable analogs of pyrophosphate and are potent inhibitors of bone resorption and bone turnover. They are used widely in treatment of osteoporosis in adults, and have reduced the risk of fractures in women with postmenopausal osteoporosis, men with osteoporosis, and patients with glucocorticoid-induced osteoporosis in multiple clinical trials.",
"   </p>",
"   <p>",
"    Reports of bisphosphonates for children with OI are encouraging, with a reduced fracture frequency of up to 100 percent in observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The long-term effects on structural outcomes such as scoliosis and basilar invagination are unclear. The optimal dose range, dosing interval, duration of treatment, and the long-term efficacy and safety profile of these drugs in the treatment OI have yet to be established. Further study, particularly in the form of randomized trials, is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13635530\">",
"    <span class=\"h2\">",
"     IV pamidronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of information about the use of bisphosphonates in OI comes from uncontrolled studies of cyclical infusions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    in various regimens in children with OI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/9\">",
"     9",
"    </a>",
"    ]. These reports have noted increased bone mineral density (BMD), decreased fracture rate, and improved functional abilities, mobility, ambulation, and pain, without negative effects on fracture healing or growth rate in most studies, even when used in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/8,10-18\">",
"     8,10-18",
"    </a>",
"    ]. A single observational study of 14 prepubertal children with mild forms of OI (types I and IV) treated with pamidronate found a significant increase in height and sitting height standard deviation scores during the first year of treatment.",
"   </p>",
"   <p>",
"    In the only controlled trial, 18 children (age range 4 to 13 years) with types III and IV OI were randomly assigned to treatment with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per day for three days every three months) or no treatment for one year; four children in each group also received recombinant growth hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/19\">",
"     19",
"    </a>",
"    ]. After one year, treated patients had significantly increased lumbar spine BMD, midvertebral height, and total vertebral area, compared with controls. Upper extremity fracture rate decreased significantly in the first, but not second, year of treatment compared with the baseline rate (0.89 at baseline, and 0.22 and 0.29 after one and two years of treatment, respectively). There was a trend toward decreased fracture rate in the lower extremities in the first year of treatment compared with baseline (1.44 versus 0.67 respectively). Growth rate, gross motor function, muscle strength, and pain did not change significantly in treated patients compared to controls. In the seven patients who extended treatment for an additional 6 to 12 months, bone density, midvertebral height, and vertebral area were maintained, but did not increase beyond the 12-month values.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     Pamidronate",
"    </a>",
"    is administered intravenously in cycles of three consecutive days at two to four month intervals with doses ranging from 0.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    to 1",
"    <span class=\"nowrap\">",
"     mg/kg/day,",
"    </span>",
"    depending upon age, with a corresponding annual dose of 9",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    The smallest effective dose should be used with careful monitoring of vertebral geometry, long bone fractures, and BMD before imitating a new cycle of treatment.",
"   </p>",
"   <p>",
"    Among the short-term endocrine and metabolic effects of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    therapy that were observed in 165 children (age 2 weeks to 17.9 years) who received cyclic infusions were [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Short-lived lowering of serum calcium concentrations following three sequential daily infusions (none requiring supplemental intravenous calcium)",
"     </li>",
"     <li>",
"      Increased parathyroid hormone (PTH) levels",
"     </li>",
"     <li>",
"      Increased 1-25 dihydroxy vitamin D levels",
"     </li>",
"     <li>",
"      Decreased urinary excretion of type I collagen degradation products (N-telopeptide of type I collagen, NTX), a marker of bone turnover",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Over the longer term (at least four years of therapy in 40 patients) there was no significant overall change in serum calcium concentrations from baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/20\">",
"     20",
"    </a>",
"    ]. Mean PTH levels were elevated by 30 percent from baseline and subsequently remained stable. The excretion of NTX adjusted for urinary creatinine decreased rapidly during the first year and more slowly thereafter. After four years of bisphosphonate therapy, the adjusted urinary NTX was 63 percent lower than the baseline value and was lower than that in healthy children, indicating a sustained reduction in the rate of bone turnover that is increased in OI children.",
"   </p>",
"   <p>",
"    A similar association between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    therapy and decreased bone turnover was found in a study of 29 children with OI types I, III, and IV who were treated with pamidronate for three years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/13\">",
"     13",
"    </a>",
"    ]. Treatment was initiated before two years of age. Treatment with pamidronate was associated with improved bone strength and gross motor function. However, the average bone formation rate per bone surface in the treated children was 17 percent that of children with severe OI who were untreated, and 25 percent that of healthy controls.",
"   </p>",
"   <p>",
"    There do not appear to be any adverse short-term effects on bone quality or fracture healing despite the significant reduction in the rate of bone turnover with bisphosphonate treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/21\">",
"     21",
"    </a>",
"    ]. Iliac bone biopsy results in 45 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    for a mean of 2.4 years revealed that bone formation and bone mineralization were not impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/22\">",
"     22",
"    </a>",
"    ]. Chronic suppression of bone turnover in children with OI does not appear to be associated with any detrimental effects on linear growth rate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/14,23,24\">",
"     14,23,24",
"    </a>",
"    ]. However, it appears that most of the benefit of pamidronate therapy occurs during the first two to four years of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/16,25\">",
"     16,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonetheless, it is prudent to reserve its use for patients in whom clinical benefits are likely to outweigh the long-term risks (ie, those with long-bone deformities, vertebral compression fractures, and &ge;3 fractures per year), since the long-term effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    therapy are unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/1,9,13,26\">",
"     1,9,13,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13637761\">",
"    <span class=\"h2\">",
"     IV zoledronic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    (zolendronate) requires infusion every six months, rather than monthly as with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    . The safety and efficacy of zoledronic therapy was evaluated in a study of 17 patients with mild (type I) OI aged 1.5 to 16.8 years who were treated for one to three years. Bone density increased after two years of treatment; two patients developed symptomatic hypocalcemia. Although the incidence of fractures in the two years preceding treatment was higher than during the first year of treatment (6.5 versus 4",
"    <span class=\"nowrap\">",
"     fractures/year),",
"    </span>",
"    it is difficult to determine from the reported results whether the fracture rate decreased, because of a short duration of follow-up and small number of fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20070471\">",
"    <span class=\"h2\">",
"     Oral risedronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety and efficacy of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    was evaluated in a trial in which 53 children were randomized to receive one of three doses (0.2, 1, or 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per week) of risedronate for two years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/27\">",
"     27",
"    </a>",
"    ]. BMD increased and long-bone bowing deformities decreased with increasing risedronate dose. The fracture rate decreased significantly in all three groups during the treatment period compared with the previous two years, but there was no difference among the groups. It seems reasonable to conclude that the most effective dose in this study was 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of risedronate per week.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13635551\">",
"    <span class=\"h2\">",
"     Oral alendronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of daily oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    (5 mg or 10 mg based on body weight: below or above 40 kg, respectively) was studied in 139 children, aged 4 to 18 years, with severe OI in a randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/28\">",
"     28",
"    </a>",
"    ]. After two years of treatment, alendronate produced a significant increase in lumbar spine BMD compared with placebo (51 versus 12 percent). However, there were no significant differences between groups with regard to growth velocity, incidence of long-bone fractures, bone pain, or pediatric disability score. The safety and tolerability of alendronate were favorable and comparable to that of placebo. Longer-term data, including bone biopsies, fracture incidence, and fracture healing will be required to fully assess the bone safety and efficacy of alendronate in OI children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20070374\">",
"    <span class=\"h2\">",
"     IV neridronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of treatment with intravenous neridronate were evaluated in a trial in which 64 prepubertal Italian children (6 to 11 years) with OI were randomly assigned to treatment with neridronate (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    infused intravenously every three months) or no treatment for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/29\">",
"     29",
"    </a>",
"    ], after which all patients were treated with neridronate. At the end of the first year, patients in the treatment group had greater increase in spine and hip BMD (18 to 25 percent versus 3 to 6 percent), and fewer fractures (relative risk 0.36, 95% CI 0.15-0.87) compared with the control group. Neridronate was well tolerated in this study. Neridronate is not available in the United States.",
"   </p>",
"   <p>",
"    The efficacy of cyclical neridronate therapy in infants was evaluated in a study in which 10 infants with OI type III started cyclical neridronate just after diagnosis (at approximately one month of age) or at six months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/30\">",
"     30",
"    </a>",
"    ]. These infants were compared to historical controls matched for age, sex, and clinical severity. During the first six months, infants receiving neridronate had better growth in weight and height and fewer fractures than those waiting to start therapy or historical controls. During the second six months, infants in both of the treatment groups had fewer fractures than historical controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20070426\">",
"    <span class=\"h2\">",
"     Oral olpadronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results similar to those with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    were reported with oral olpadronate in three boys with severe OI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/31\">",
"     31",
"    </a>",
"    ]. In a trial in which 34 children with OI were randomly assigned to olpadronate (10",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    or placebo, active treatment for two years was associated with a reduced risk of long-bone fractures (hazard ratio 0.69, 95% CI 0.52-0.91) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/32\">",
"     32",
"    </a>",
"    ]. There was no effect on vertebral height, children's function, or markers of bone turnover. Olpadronate is not available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13635558\">",
"    <span class=\"h2\">",
"     Intravenous versus oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data directly comparing intravenous and oral bisphosphonate therapy in children with OI. In one small, randomized trial comparing oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    to IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    for children with OI, BMD increased similarly in both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/33\">",
"     33",
"    </a>",
"    ]. Nonetheless, many clinicians believe that intravenous pamidronate is more effective in treating bone pain and possibly has a greater effect on fracture risk reduction than oral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13635572\">",
"    <span class=\"h2\">",
"     In adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults with OI may have a higher fracture risk than healthy peers because they are unlikely to reach an equivalent peak BMD. In addition, the structural defects of collagen may contribute to decreased bone strength, independently of BMD, thereby increasing the risk of fractures. Postmenopausal bone loss beginning from a lower-than-normal peak may increase fracture risk in untreated women with OI compared with postmenopausal women in general. Thus, treatment with selective estrogen receptor modulators (SERMS) or bisphosphonates should be considered immediately after menopause to prevent accelerated bone loss and osteoporotic fractures in women with the superimposed problems of postmenopausal osteoporosis and OI (self-history or family history). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Little information on treatment in adults with OI is available. In one study, 23 men and 23 premenopausal women with OI (types I, III, and IV) were randomized to IV neridronate 100 mg every three months or no treatment (ratio 2 to 1) for a period of one year, with both groups receiving treatment the second year [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/34\">",
"     34",
"    </a>",
"    ]. The average age of the population was 35 years, and mean lumbar spine BMD T-score was -3.4. BMD increased significantly from baseline in the treatment group and compared with the control group. After two years, BMD increased 6.4 percent and 7.5 percent in males and females, respectively, in the treatment group. The risk of clinical fractures tended to decrease during treatment with neridronate, although the study was not powered for such an endpoint. Neridronate is not available in the United States.",
"   </p>",
"   <p>",
"    In an observational study, 90 adults with OI (types I, III, and IV) were treated with IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    (n = 28), oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    (n = 10), oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    (n = 17), or not treated (n = 35) for an average of 52 months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/35\">",
"     35",
"    </a>",
"    ]. A significantly increasing rate of BMD per year of treatment was seen in all types of OI treated with pamidronate, but only in patients with type I OI treated with oral bisphosphonates. Fracture rate decreased significantly only in the type",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    patients treated with pamidronate.",
"   </p>",
"   <p>",
"    Off-label bisphosphonate treatment of adults with OI must be considered on a case-by-case basis and in general should be based upon the assessment of fracture risk using BMD and clinical risk factors such as history of nontraumatic fracture, family history of osteoporosis, weight, smoking, and alcohol consumption in addition to the risk associated with OI. The relative contribution of OI, besides low BMD, to the fracture risk in adults as a result of defective bone quality is unknown. Nevertheless, we suggest that the therapeutic threshold should be lower for adults with OI with the same level of fracture risk as compared with those without OI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link\">",
"     \"Osteoporotic fracture risk assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13635586\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    therapy include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An influenza-like syndrome (fever, myalgias, malaise, rash, vomiting) following the first infusion [",
"      <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/10,14,24\">",
"       10,14,24",
"      </a>",
"      ]. This likely reflects acute cytokine release in a subset of patients with a genetic profile that has yet to be identified. It is seen after the first dose and is unlikely to occur with subsequent doses. This influenza-like syndrome was also seen after the first dose of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"       ibandronate",
"      </a>",
"      in the monthly dosing clinical trial and is recorded in the product label.",
"     </li>",
"     <li>",
"      Unexplained rapid weight gain that may interfere with rehabilitation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Uveitis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/1\">",
"       1",
"      </a>",
"      ]. This adverse effect resolves with discontinuation of the drug.",
"     </li>",
"     <li>",
"      Respiratory distress in infants younger than two years [",
"      <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of adverse musculoskeletal events are associated with bisphosphonate use in adults. The most serious among them is osteonecrosis of the jaw (ONJ), which is primarily associated with intravenous bisphosphonate use in cancer patients who may have jawbone vulnerability resulting from radiation therapy to the head and neck or from cancer chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. However, ONJ has also been reported in some patients on oral bisphosphonates for osteoporosis; therefore, it is important to document good dental health before commencing bisphosphonate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. A chart review study in 15 children (age range 2 to 16 years) with OI who had received bisphosphonates either prior to or during dental extractions (a total of 60 extractions, mostly primary teeth) did not identify any evidence of osteonecrosis of the jaw [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/41\">",
"     41",
"    </a>",
"    ]. The healing time was normal and no complications were recorded. Further studies are needed to assess the risk of this rare event in children with OI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H1928329#H1928329\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Osteonecrosis of the jaw'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are reports of atypical long-bone fractures, particularly in the subtrochanteric area of the femur, after long-term use of bisphosphonates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Both ONJ and the atypical long-bone fractures may be related, at least in part, to significant suppression of bone turnover that interferes with normal bone repair and renewal processes.",
"   </p>",
"   <p>",
"    Finally, bone, joint, and muscle pains (referred to as the musculoskeletal syndrome) have been reported with bisphosphonate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In some patients, the musculoskeletal syndrome is seen early in therapy, is tolerated, and goes away with time. In other patients, the musculoskeletal syndrome may lead to discontinuation of bisphosphonate BP therapy.",
"   </p>",
"   <p>",
"    Neither ONJ nor atypical fractures have been reported in children with OI treated with bisphosphonates, and the pathogenesis of these conditions has not been clearly established. Nevertheless, these musculoskeletal adverse events should be kept in mind when prescribing bisphosphonates to children or adults with OI.",
"   </p>",
"   <p>",
"    The safety of bisphosphonates in postmenopausal women is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1602007\">",
"    <span class=\"h1\">",
"     ORTHOPEDIC AND OTHER SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experienced orthopedic surgeons with an interest in OI are ideal to helping OI patients reach the highest functional level possible. A list of clinics specializing in OI is available on the Osteogenesis Imperfecta Foundation website (",
"    <a class=\"external\" href=\"file://www.oif.org/\">",
"     www.oif.org",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Typical orthopedic services that are provided in integrated, coordinated clinical care centers for OI include management of fractures (with quick mobilization to prevent bone loss due to inactivity) and placement of intramedullary rods to prevent or correct long-bone deformities. Telescoping rods may be appropriate for patients older than two years who are actively growing. Patients with severe scoliosis also may benefit from surgery in carefully selected cases.",
"   </p>",
"   <p>",
"    Basilar skull deformity that causes nerve compression or other neurologic symptoms may require neurosurgical correction. Similarly, for those with hearing loss, the service of an otolaryngologist may be needed. Stapedotomy may be appropriate for some patients with predominantly conductive hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1602034\">",
"    <span class=\"h2\">",
"     Fracture management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of fractures in patients with OI is similar to the management of fractures in patients without OI. Early mobilization is particularly important to prevent bone loss secondary to inactivity.",
"   </p>",
"   <p>",
"    The clinical features and management of specific fractures are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6320228\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some anesthesia risks are associated with patients with OI that distinguish them from the general population, although, in general, anesthesia is safe and well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/6\">",
"     6",
"    </a>",
"    ]. Chest deformities and scoliosis may compromise breathing. Small stature will determine the choice of equipment. Some patients with OI may show increases in body temperature during and after surgery. The reason for this is unclear. Precautions such as avoiding warming blankets or heavy drapes are often effective in these cases. Some anesthetics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    should be avoided, if possible, since they could exacerbate increased body temperature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PHYSICAL AND OCCUPATIONAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The services of trained rehabilitation experts are essential to successfully treat the many domains affected in OI patients. The results of",
"    <span class=\"nowrap\">",
"     PT/OT",
"    </span>",
"    interventions are not always dramatic, but the children and their parents appreciate even small advances that can be quite meaningful to them in the long term.",
"   </p>",
"   <p>",
"    Physical therapists can be instrumental in designing a physical activity program that minimizes fracture risk while ensuring mobilization to prevent contractures and bone loss from immobility [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Occupational therapists can address the impairments in activities of daily living secondary to upper or lower limb deformity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1602110\">",
"    <span class=\"h1\">",
"     PSYCHOSOCIAL ASPECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consideration of the psychosocial aspects of OI is another important component of long-term care [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/47\">",
"     47",
"    </a>",
"    ]. The extent to which individuals with OI feel stigmatized by being physically different from their peers depends upon their disease severity, natural history, and degree to which it affects physical appearance and socialization, and whether or not other family members are affected [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/47\">",
"     47",
"    </a>",
"    ]. Parents may have been suspected of child abuse in cases where the diagnosis is delayed, leading to feelings of guilt, frustration, and anxiety.",
"   </p>",
"   <p>",
"    Trying to balance the risk of fracture with the performance of routine activities, such as school attendance, can be difficult. Contact sports should be avoided, and other activities are restricted based upon the severity of the condition. Adolescence can be particularly troublesome, when concerns about appearance, sexual development, and peer acceptance are paramount [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/47\">",
"     47",
"    </a>",
"    ]. During young adulthood, problems related to immobility and social and financial dependence become more pressing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for patients with OI and their families may include the provision of information, contact with other patients and their families, and referrals for formal or informal counseling or respite care [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/4,47\">",
"     4,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1602117\">",
"    <span class=\"h2\">",
"     Resources",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following information on resources and support groups is available for patients and parents of patients with OI:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Osteogenesis Imperfecta Foundation (",
"      <a class=\"external\" href=\"file://www.oif.org/\">",
"       www.oif.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      National Organization for Rare Disorders (",
"      <a class=\"external\" href=\"file://www.rarediseases.org/\">",
"       www.rarediseases.org",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2334333\">",
"    <span class=\"h1\">",
"     PRIMARY CARE CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary care of children with osteogenesis imperfecta requires some special considerations. In addition to routine care and immunizations, special attention should be paid to the following aspects of the examination and health supervision [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Growth and head circumference.",
"     </li>",
"     <li>",
"      Hearing (formal audiology initially at nine months of age and then at regular intervals as described below).",
"     </li>",
"     <li>",
"      Vision screening every two to three years, with referral to an ophthalmologist as indicated by clinical findings.",
"     </li>",
"     <li>",
"      Developmental monitoring, with referral to early intervention services for those younger than three years, and referral to physical therapy and occupational therapy as needed for those older than three years. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Physical and occupational therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pneumococcal and influenza vaccination should be considered if there are no contraindications. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link\">",
"       \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=see_link\">",
"       \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"       \"Pneumococcal vaccination in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"       \"Seasonal influenza vaccination in children\", section on 'Indications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"       \"Seasonal influenza vaccination in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Provision of dental referral as indicated for dentinogenesis imperfecta.",
"     </li>",
"     <li>",
"      Help with transitions to preschool and school; chronic illness and physical disability may affect school performance. Children with OI should receive an educational program to address these issues [",
"      <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The care and support services for children with chronic illness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    special health care needs are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32679?source=see_link\">",
"     \"Support services for the care of chronically ill children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27737?source=see_link&amp;anchor=H5#H5\">",
"     \"Children with special health care needs\", section on 'Implications of chronic conditions in childhood'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13636412\">",
"    <span class=\"h1\">",
"     MONITORING FOR COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with OI should undergo regular surveillance for potential complications (eg, hearing loss, worsening of osteoporosis) so that appropriate intervention is initiated as soon as possible.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest a hearing test to evaluate for conductive and sensorineural hearing loss, dual energy absorptiometry (DEXA) to assess bone mineral density, and spirometry to monitor for restrictive defects secondary to rib and vertebral fractures every two years (or sooner if clinically indicated), particularly in patients with moderate to severe OI. BMD was related to disease severity (functional outcome, rate of fracture, and rate of surgery) in one review of patients with OI who completed a questionnaire [",
"      <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/49\">",
"       49",
"      </a>",
"      ]. Appropriate referrals should be made",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pharmacologic therapies initiated when abnormalities are detected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29927?source=see_link\">",
"       \"Treatment of hearing impairment in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39300?source=see_link\">",
"       \"Hearing amplification in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with type III (",
"      <a class=\"graphic graphic_table graphicRef78737 \" href=\"UTD.htm?20/3/20541\">",
"       table 1",
"      </a>",
"      ) deforming OI or other moderate to severe types of OI should have yearly spirometry and an electrocardiogram and an echocardiogram every two years (to detect aortic root dilation and valvular dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]).",
"     </li>",
"     <li>",
"      Basilar skull deformity could lead to basilar invagination. Thus, neurologic examination and cranial assessment should be performed as indicated by symptoms or behavioral changes, particularly in patients with type III OI and other forms with a similar phenotype (types VII to IX).",
"     </li>",
"     <li>",
"      Skeletal radiographs should be performed at the time of diagnosis and then every one to two years (or sooner if clinically indicated) and coordinated with orthopedic advice. (See",
"      <a class=\"local\" href=\"#H1602007\">",
"       'Orthopedic and other surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children receiving bisphosphonate treatment should have yearly (or more frequently as clinically indicated) assessment of BMD and radiologic assessment of long bones and spine to determine the effect of treatment on vertebral geometry, long bone fractures, and changes in bone mass.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Growth hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of growth hormone (GH) in OI has been studied in small groups of patients since 1975, although it is still viewed as an experimental therapy. The theoretical basis for using GH is to stimulate bone formation and also to increase stature. No studies have extended beyond two years.",
"   </p>",
"   <p>",
"    In a single randomized trial, 30 prepubertal children with OI (types I, III, and IV) were observed for 12 months during ongoing neridronate therapy and then randomized to recombinant GH (rGH) plus neridronate or neridronate alone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/52\">",
"     52",
"    </a>",
"    ]. Bone mineral density and growth velocity were significantly higher in the group that received GH compared with the control group, although no difference was seen in the fracture risk rate. The increase in bone age was similar in both groups.",
"   </p>",
"   <p>",
"    A summary of experience with GH therapy for OI included one investigator's experience with 22 OI patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/53\">",
"     53",
"    </a>",
"    ]. In this series, treatment with GH had beneficial effects on bone turnover, bone mineral density, and height velocity rate. Another series of 26 children with type III or type IV OI (",
"    <a class=\"graphic graphic_table graphicRef78737 \" href=\"UTD.htm?20/3/20541\">",
"     table 1",
"    </a>",
"    ) of moderate severity received GH (0.1 to 0.2",
"    <span class=\"nowrap\">",
"     IU/kg",
"    </span>",
"    per day for six of seven days per week) for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/54\">",
"     54",
"    </a>",
"    ]. Roughly one-half of the children responded with an increase in linear growth rate of 50 percent or more from their pretreatment rate. Those who had such an increase in growth also had increased vertebral bone mineral density and decreased fracture rates. Higher levels of procollagen carboxy terminal propeptides (PICP) were correlated with a growth response to GH. A cut-off level of PICP of 86",
"    <span class=\"nowrap\">",
"     microgram/mL",
"    </span>",
"    was 73 percent predictive of a response to growth hormone administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Cell replacement therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pilot study of allogeneic hematopoietic cell transplantation (HCT) was performed in five children with OI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/55\">",
"     55",
"    </a>",
"    ]. Three children had successful engraftment, and in these three, improvements in growth velocity and reduction in fracture rate were noted following transplantation. Engrafting allogeneic mesenchymal cells may provide another avenue to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series of six patients with severe OI who received allogeneic bone marrow transplantation, donor-derived mesenchymal cells that incorporated a reporter gene were subsequently recovered from skin, bone, and bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/57\">",
"     57",
"    </a>",
"    ]. Linear growth was more rapid following the mesenchymal cell infusions than in the six-month period between the marrow transplantations and the first of two infusions of mesenchymal cells.",
"   </p>",
"   <p>",
"    Although transplantation of mesenchymal stem cells or bone marrow stromal cells have a good theoretical basis for correcting genetic defects of bone and cartilage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/58,59\">",
"     58,59",
"    </a>",
"    ], more clinical research is needed before these therapies can be recommended for patients with OI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antisense therapy and gene targeting have been evaluated in animal models of OI. The goal of antisense therapy in OI is to suppress or silence a particular mutant allele of the type I collagen gene and not interfere with the expression of the normal allele [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/60\">",
"     60",
"    </a>",
"    ]. Thus, a severe form of OI could potentially be turned into a mild form of the disease. Small molecules with complementary sequences are used to bind and sequester the target messenger RNA, thus preventing translation of the defective collagen precursor.",
"   </p>",
"   <p>",
"    Another approach under exploration is gene targeting of the patient's mesenchymal stem cells. In a preliminary study, adeno-associated virus vectors successfully disrupted the mutated allele ex vivo in mesenchymal stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/61\">",
"     61",
"    </a>",
"    ]. Infusion of these cells into a mouse model resulted in bone formation. There are several potential problems associated with such a gene-targeting approach that need to be addressed before this technique can be applied to patients with OI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis depends upon the type of OI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26185/abstract/63\">",
"     63",
"    </a>",
"    ]. Patients with mild OI (type I, (",
"    <a class=\"graphic graphic_table graphicRef78737 \" href=\"UTD.htm?20/3/20541\">",
"     table 1",
"    </a>",
"    )) typically have a few childhood fractures, no long-bone deformity, and a normal life expectancy. Patients with moderate to severe (types III- to IX, (",
"    <a class=\"graphic graphic_table graphicRef78737 \" href=\"UTD.htm?20/3/20541\">",
"     table 1",
"    </a>",
"    )) have an increased risk of premature death in both childhood and adult life compared with the general population.",
"   </p>",
"   <p>",
"    Shortened life span may be related to immobility and thoracic deformities in a subset of patients with moderately severe disease. These problems create an increased risk of severe pulmonary infections and subsequent loss of lung function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goals of therapy for patients with osteogenesis imperfecta (OI) are to reduce fracture rates, prevent long-bone deformities and scoliosis, minimize pain, and to maximize mobility and other functional capabilities. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bisphosphonates are the mainstay of pharmacologic fracture-prevention therapy for most forms of OI (except for type VI (",
"      <a class=\"graphic graphic_table graphicRef78737 \" href=\"UTD.htm?20/3/20541\">",
"       table 1",
"      </a>",
"      ) in which bone mineralization is defective), although none are approved specifically for use in either children or adults with OI. Little information on treatment in adults with OI is available. The optimal dose range, dosing interval, duration of treatment, and the long-term efficacy and safety profile have yet to be established. We suggest treatment with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      for patients with all forms of OI, except type VI, in whom clinical benefits are likely to outweigh potential long-term risks (ie, those with long-bone deformities, vertebral compression fractures, and &ge;3 fractures per year) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The suggested duration of treatment is two to four years. The decision to use these drugs is best made by specialists at medical centers with significant experience in treating OI.",
"     </li>",
"     <li>",
"      Treatment requires a coordinated, multidisciplinary team approach and consists of physical therapy, surgical interventions, medications, and, in some cases, experimental therapies. Patients with OI and parents of patients with OI should be advised to seek care in specialty medical centers with significant experience in treating OI. A list of clinics specializing in OI is available on the Osteogenesis Imperfecta Foundation website (",
"      <a class=\"external\" href=\"file://www.oif.org/\">",
"       www.oif.org",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1602007\">",
"       'Orthopedic and other surgery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Physical and occupational therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1602110\">",
"       'Psychosocial aspects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2334333\">",
"       'Primary care considerations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Experimental therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with OI should undergo regular surveillance for potential complications so that appropriate intervention can be initiated as soon as possible (See",
"      <a class=\"local\" href=\"#H13636412\">",
"       'Monitoring for complications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2334333\">",
"       'Primary care considerations'",
"      </a>",
"      above.). This includes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Regular monitoring of growth and head circumference",
"     </li>",
"     <li>",
"      Hearing test, assessment of bone mineral density, and spirometry every two years, particularly in patients with moderate to severe OI",
"     </li>",
"     <li>",
"      Electrocardiogram and echocardiogram every two years and yearly spirometry in all patients with type III OI and other moderate to severe types (VII to IX) (",
"      <a class=\"graphic graphic_table graphicRef78737 \" href=\"UTD.htm?20/3/20541\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Neurologic examination and cranial assessment as indicated by symptoms or behavioral changes",
"     </li>",
"     <li>",
"      Skeletal radiographs at the time of diagnosis and then every one to two years (or sooner if clinically indicated) and coordinated with orthopedic advice",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prognosis depends upon the type of OI, ranging from a normal life expectancy in patients with type I OI to perinatal mortality in patients with type II OI (",
"      <a class=\"graphic graphic_table graphicRef78737 \" href=\"UTD.htm?20/3/20541\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Prognosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=see_link&amp;anchor=H6#H6\">",
"       \"Osteogenesis imperfecta: Clinical features and diagnosis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/1\">",
"      Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004; 363:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/2\">",
"      Engelbert RH, Pruijs HE, Beemer FA, Helders PJ. Osteogenesis imperfecta in childhood: treatment strategies. Arch Phys Med Rehabil 1998; 79:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/3\">",
"      Engelbert RH, Beemer FA, van der Graaf Y, Helders PJ. Osteogenesis imperfecta in childhood: impairment and disability--a follow-up study. Arch Phys Med Rehabil 1999; 80:896.",
"     </a>",
"    </li>",
"    <li>",
"     Osteogenesis imperfecta. In: Preventive management of children with congenital anomalies and syndromes, Wilson GN, Cooley WC (Eds), Cambridge University Press, Cambridge, UK 2000. p.256.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/5\">",
"      Zeitlin L, Fassier F, Glorieux FH. Modern approach to children with osteogenesis imperfecta. J Pediatr Orthop B 2003; 12:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/6\">",
"      Monti E, Mottes M, Fraschini P, et al. Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag 2010; 6:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/7\">",
"      Bishop N. Characterising and treating osteogenesis imperfecta. Early Hum Dev 2010; 86:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/8\">",
"      Salehpour S, Tavakkoli S. Cyclic pamidronate therapy in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2010; 23:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/9\">",
"      Rauch F, Glorieux FH. Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long? Ann Med 2005; 37:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/10\">",
"      Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/11\">",
"      Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000; 85:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/12\">",
"      DiMeglio LA, Ford L, McClintock C, Peacock M. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 2004; 35:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/13\">",
"      Munns CF, Rauch F, Travers R, Glorieux FH. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res 2005; 20:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/14\">",
"      Astr&ouml;m E, S&ouml;derh&auml;ll S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002; 86:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/15\">",
"      Zeitlin L, Rauch F, Travers R, et al. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V. Bone 2006; 38:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/16\">",
"      Vallo A, Rodriguez-Leyva F, Rodr&iacute;guez Soriano J. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy. Acta Paediatr 2006; 95:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/17\">",
"      Land C, Rauch F, Montpetit K, et al. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. J Pediatr 2006; 148:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/18\">",
"      Astr&ouml;m E, Jorulf H, S&ouml;derh&auml;ll S. Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta. Arch Dis Child 2007; 92:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/19\">",
"      Letocha AD, Cintas HL, Troendle JF, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 2005; 20:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/20\">",
"      Rauch F, Plotkin H, Travers R, et al. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 2003; 88:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/21\">",
"      Pizones J, Plotkin H, Parra-Garcia JI, et al. Bone healing in children with osteogenesis imperfecta treated with bisphosphonates. J Pediatr Orthop 2005; 25:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/22\">",
"      Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002; 110:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/23\">",
"      Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003; 111:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/24\">",
"      Zacharin M, Bateman J. Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab 2002; 15:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/25\">",
"      Rauch F, Travers R, Glorieux FH. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J Clin Endocrinol Metab 2006; 91:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/26\">",
"      Lindsay R. Modeling the benefits of pamidronate in children with osteogenesis imperfecta. J Clin Invest 2002; 110:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/27\">",
"      Bishop N, Harrison R, Ahmed F, et al. A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. J Bone Miner Res 2010; 25:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/28\">",
"      Ward LM, Rauch F, Whyte MP, et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab 2011; 96:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/29\">",
"      Gatti D, Antoniazzi F, Prizzi R, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 2005; 20:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/30\">",
"      Antoniazzi F, Zamboni G, Lauriola S, et al. Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. J Pediatr 2006; 149:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/31\">",
"      Landsmeer-Beker EA, Massa GG, Maaswinkel-Mooy PD, et al. Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Eur J Pediatr 1997; 156:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/32\">",
"      Sakkers R, Kok D, Engelbert R, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 2004; 363:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/33\">",
"      Dimeglio LA, Ford L, McClintock C, Peacock M. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2005; 18:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/34\">",
"      Adami S, Gatti D, Colapietro F, et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 2003; 18:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/35\">",
"      Shapiro JR, Thompson CB, Wu Y, et al. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. Calcif Tissue Int 2010; 87:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/36\">",
"      Munns CF, Rauch F, Mier RJ, Glorieux FH. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 2004; 35:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/37\">",
"      Khan EA, Blake JW, Stamp LK. Ticlopidine as a safe alternative for clopidogrel-associated arthritis. J Rheumatol 2009; 36:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/38\">",
"      Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 2009; 122:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/39\">",
"      Kunchur R, Goss AN. The oral health status of patients on oral bisphosphonates for osteoporosis. Aust Dent J 2008; 53:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/40\">",
"      Edwards BJ, Hellstein JW, Jacobsen PL, et al. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2008; 139:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/41\">",
"      Schwartz S, Joseph C, Iera D, Vu DD. Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: a case series. J Can Dent Assoc 2008; 74:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/42\">",
"      Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007; 89:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/43\">",
"      Neviaser AS, Lane JM, Lenart BA, et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008; 22:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/44\">",
"      Ward L, Tricco AC, Phuong P, et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev 2007; :CD005324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/45\">",
"      Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 2005; 165:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/46\">",
"      Albahnasawy L, Kishore A, O'Reilly BF. Results of stapes surgery on patients with osteogenesis imperfecta. Clin Otolaryngol Allied Sci 2001; 26:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/47\">",
"      Cole DE. Psychosocial aspects of osteogenesis imperfecta: an update. Am J Med Genet 1993; 45:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/48\">",
"      Schild S. The challenging opportunity for social workers in genetics. Social Work 1966; 4:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/49\">",
"      Huang RP, Ambrose CG, Sullivan E, Haynes RJ. Functional significance of bone density measurements in children with osteogenesis imperfecta. J Bone Joint Surg Am 2006; 88:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/50\">",
"      Vetter U, Maierhofer B, M&uuml;ller M, et al. Osteogenesis imperfecta in childhood: cardiac and renal manifestations. Eur J Pediatr 1989; 149:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/51\">",
"      Hortop J, Tsipouras P, Hanley JA, et al. Cardiovascular involvement in osteogenesis imperfecta. Circulation 1986; 73:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/52\">",
"      Antoniazzi F, Monti E, Venturi G, et al. GH in combination with bisphosphonate treatment in osteogenesis imperfecta. Eur J Endocrinol 2010; 163:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/53\">",
"      Antoniazzi F, Mottes M, Fraschini P, et al. Osteogenesis imperfecta: practical treatment guidelines. Paediatr Drugs 2000; 2:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/54\">",
"      Marini JC, Hopkins E, Glorieux FH, et al. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen. J Bone Miner Res 2003; 18:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/55\">",
"      Horwitz EM, Prockop DJ, Gordon PL, et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001; 97:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/56\">",
"      Otsuru S, Gordon PL, Shimono K, et al. Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. Blood 2012; 120:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/57\">",
"      Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002; 99:8932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/58\">",
"      Vanleene M, Saldanha Z, Cloyd KL, et al. Transplantation of human fetal blood stem cells in the osteogenesis imperfecta mouse leads to improvement in multiscale tissue properties. Blood 2011; 117:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/59\">",
"      Illich DJ, Demir N, Stojkovi M, et al. Concise review: induced pluripotent stem cells and lineage reprogramming: prospects for bone regeneration. Stem Cells 2011; 29:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/60\">",
"      Wang Q, Marini JC. Antisense oligodeoxynucleotides selectively suppress expression of the mutant alpha 2(I) collagen allele in type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders. J Clin Invest 1996; 97:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/61\">",
"      Chamberlain JR, Schwarze U, Wang PR, et al. Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science 2004; 303:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/62\">",
"      Prockop DJ. Targeting gene therapy for osteogenesis imperfecta. N Engl J Med 2004; 350:2302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26185/abstract/63\">",
"      Singer RB, Ogston SA, Paterson CR. Mortality in various types of osteogenesis imperfecta. J Insur Med 2001; 33:216.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2915 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-41275854C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_36_26185=[""].join("\n");
var outline_f25_36_26185=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13635515\">",
"      BISPHOSPHONATE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13635530\">",
"      IV pamidronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13637761\">",
"      IV zoledronic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20070471\">",
"      Oral risedronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13635551\">",
"      Oral alendronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20070374\">",
"      IV neridronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20070426\">",
"      Oral olpadronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13635558\">",
"      Intravenous versus oral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13635572\">",
"      In adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13635586\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1602007\">",
"      ORTHOPEDIC AND OTHER SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1602034\">",
"      Fracture management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6320228\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PHYSICAL AND OCCUPATIONAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1602110\">",
"      PSYCHOSOCIAL ASPECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1602117\">",
"      Resources",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2334333\">",
"      PRIMARY CARE CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13636412\">",
"      MONITORING FOR COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      EXPERIMENTAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Growth hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Cell replacement therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Gene therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2915\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2915|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/3/20541\" title=\"table 1\">",
"      OI clinical features",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27737?source=related_link\">",
"      Children with special health care needs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39300?source=related_link\">",
"      Hearing amplification in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38040?source=related_link\">",
"      Osteogenesis imperfecta: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32679?source=related_link\">",
"      Support services for the care of chronically ill children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29927?source=related_link\">",
"      Treatment of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_36_26186="Breast cancer in men";
var content_f25_36_26186=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Breast cancer in men",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/36/26186/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/36/26186/contributors\">",
"     William J Gradishar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/36/26186/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/36/26186/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/36/26186/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/36/26186/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/36/26186/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/36/26186/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/36/26186/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer in men is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/1\">",
"     1",
"    </a>",
"    ]. Although it shares many similarities with cancer of the breast in women, there are also important differences [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, approximately 2140 new cases of breast cancer in men are diagnosed annually, and 450 deaths occur; this represents less than 0.5 percent of all cancer deaths in men annually [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/1\">",
"     1",
"    </a>",
"    ]. By contrast, in Tanzania and areas of central Africa, breast cancer accounts for up to 6 percent of cancers in men [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, the ratio of female to male breast cancer is approximately 100:1 in whites, but lower (70:1) in blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Blacks also have a poorer prognosis, even after adjustment for clinical, demographic, and treatment factors. (See",
"    <a class=\"local\" href=\"#H38\">",
"     'Racial disparities'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The median age of onset of breast cancer in men is 65 to 67, approximately 5 to 10 years older than in women [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/2,4-9\">",
"     2,4-9",
"    </a>",
"    ]. Like female breast cancer, the incidence of breast cancer in men has been increasing; one report suggests that incidence has increased 26 percent over the past 25 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of men with breast cancer have no identifiable risk factors, several have been identified, many related to hormone levels. Many of these risk factors are the same as in women, including family history, Jewish ancestry, obesity, low levels of physical activity, prior chest wall irradiation, and benign breast disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/3,11\">",
"     3,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other risk factors that are modestly unique to men include never being married, gynecomastia, and a history of testicular or liver pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/3\">",
"     3",
"    </a>",
"    ], a history of a bone fracture after age 45 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/11\">",
"     11",
"    </a>",
"    ], and Klinefelter&rsquo;s syndrome: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gynecomastia, which is most often drug-related (",
"      <a class=\"graphic graphic_table graphicRef71421 \" href=\"UTD.htm?20/35/21053\">",
"       table 1",
"      </a>",
"      ), may be associated with the development of breast cancer because of shared hormonal risk factors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/9/6294?source=see_link\">",
"       \"Epidemiology and pathogenesis of gynecomastia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27384?source=see_link\">",
"       \"Causes and evaluation of gynecomastia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Testicular conditions associated with an increased risk of breast cancer in men include orchitis, undescended testes (cryptorchidism) and testicular injury [",
"      <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/4,8,12\">",
"       4,8,12",
"      </a>",
"      ]. Among the chronic liver diseases that are associated with MBC are cirrhosis, alcoholic liver disease, and schistosomiasis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/13-17\">",
"       13-17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Klinefelter syndrome is a rare condition resulting from the inheritance of an additional X chromosome [",
"      <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/4,18-20\">",
"       4,18-20",
"      </a>",
"      ]. The Klinefelter syndrome consists of atrophic testes, gynecomastia, high serum concentrations of gonadotropins (follicle-stimulating hormone, luteinizing hormone), and low serum testosterone levels; the net effect is a high ratio of estrogen-to-testosterone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=see_link\">",
"       \"Causes of primary hypogonadism in males\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Few carefully conducted epidemiologic studies have been undertaken given the rarity of both Klinefelter syndrome and male breast cancer. The largest cohort study of 3518 men who were cytogenetically diagnosed with Klinefelter syndrome found 19- and 58-fold increases in incidence and mortality, respectively, compared to the general population, with particularly high risks among 47,XXY mosaics [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/21\">",
"     21",
"    </a>",
"    ]. Additional studies are needed to clarify which patients with Klinefelter syndrome are at a high risk of developing MBC and to define the contribution of possible predisposing factors, including altered endogenous hormones. The role of breast cancer screening in men with Klinefelter syndrome is unclear. Although the relative risk of breast cancer is increased, the absolute risk is still much lower than it is in women. Although routine mammography is not advocated for all affected men, the importance of patient education, self examination, and regular physician examinations are stressed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several of the risk factors for breast cancer in men involve imbalance in estrogenic versus androgenic influences (ie, relative estrogen excess or lack of androgen) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. As an example, men with liver disease have increased production of androstenedione from the adrenal glands, enhanced aromatization of androstenedione to estrone, and increased conversion of estrone to estradiol [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/22\">",
"     22",
"    </a>",
"    ]. On the other hand, androgens may convey a protective effect on breast tissue by inhibiting cell proliferation. The association of breast cancer in men with prolactinoma, a condition often associated with low plasma testosterone levels, is consistent with this hypothesis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is hypothesized that relative changes in endogenous hormones may play a causative role in the pathogenesis of breast cancer in men. However, abnormalities in peripherally detectable hormone levels have not been detected in affected men [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/25\">",
"     25",
"    </a>",
"    ]. Furthermore, other conditions associated with an increased estrogen-to-testosterone ratio such as obesity, thyroid disease, use of marijuana, and exogenous estrogen use (eg, transsexuals, treatment of prostate cancer) have a less certain relationship to MBC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/4,12\">",
"     4,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Inherited conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 15 to 20 percent of men with breast cancer have a family history of the disease, compared to only 7 percent of the general male population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/6\">",
"     6",
"    </a>",
"    ]. As is the case in women, two",
"    <span class=\"nowrap\">",
"     breast/ovarian",
"    </span>",
"    cancer genes, BRCA1 and BRCA2, which are inherited in an autosomal dominant pattern, are thought to account for 80 percent of multiple-case breast cancer families. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inherited mutations in BRCA also increase the risk of breast cancer in men, although not to the same absolute level of risk as in women. The risk appears to be higher with inherited BRCA2 rather than BRCA1 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/26-31\">",
"     26-31",
"    </a>",
"    ]. Men who inherit germline BRCA2 mutations have an estimated 6 percent lifetime risk of breast cancer in men; this represents a 100-fold higher risk than in the general male population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31562?source=see_link&amp;anchor=H4#H4\">",
"     \"Risk factors for prostate cancer\", section on 'Genetic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In population-based series of men with breast cancer unselected for family history, 0 to 4 percent have BRCA1 mutations, while between 5 and 15 percent have BRCA2 mutations, depending on ethnicity and the strength of the family history (",
"    <a class=\"graphic graphic_table graphicRef80912 \" href=\"UTD.htm?31/5/31836\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/28,33-42\">",
"     28,33-42",
"    </a>",
"    ]. Because of this, all men diagnosed with breast cancer should be referred for genetic counseling and BRCA testing (",
"    <a class=\"graphic graphic_table graphicRef56222 \" href=\"UTD.htm?21/58/22445\">",
"     table 3",
"    </a>",
"    ). Cancer surveillance of men with a BRCA mutation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5064?source=see_link\">",
"     \"Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=see_link\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genes other than BRCA may be involved in predisposition to MBC. Mutations in the PTEN tumor suppressor gene, which causes Cowden's syndrome, have been associated with breast cancer in men, as have mutations in TP53, which causes Li-Fraumeni syndrome, PALB2 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/43,44\">",
"     43,44",
"    </a>",
"    ], and mutations in mismatch repair genes, which are associated with hereditary nonpolyposis colorectal cancer (Lynch) syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link\">",
"     \"PTEN hamartoma tumor syndrome, including Cowden syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=see_link\">",
"     \"Li-Fraumeni syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HISTOLOGIC, BIOLOGIC, AND MOLECULAR FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most of the histologic subtypes of breast cancer that are seen in women are also present in men, the distribution is different. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16040?source=see_link\">",
"     \"Pathology of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 90 percent of breast cancers in men are invasive ductal carcinomas, while lobular histology is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/10,46-48\">",
"     10,46-48",
"    </a>",
"    ]. Lobular cancers accounted for 1.5 percent of cases in one series of 2000 men [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/10\">",
"     10",
"    </a>",
"    ], while in women, it accounts for up to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/49\">",
"     49",
"    </a>",
"    ]. The male breast can be induced to develop true acini and lobules with estrogenic stimulation, but the normal unstimulated male breast lacks these structures.",
"   </p>",
"   <p>",
"    There are also differences in the incidence and clinical characteristics of ductal carcinoma in situ (DCIS). DCIS accounts for a significantly higher proportion of breast cancers in women compared to men (approximately 20 versus 7 to 11 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/10,50,51\">",
"     10,50,51",
"    </a>",
"    ]. DCIS in men tends to occur at a later age, presents more frequently in an intraductal papillary form, and is more often low-grade [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Paget disease and inflammatory breast cancer have been rarely described in men [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/47,53-55\">",
"     47,53-55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=see_link\">",
"     \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/14?source=see_link\">",
"     \"Paget disease of the breast\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31048?source=see_link\">",
"     \"Inflammatory breast cancer: Clinical features and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hormone receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In females, 60 to 70 percent of breast cancers are estrogen receptor (ER) or progesterone receptor (PR) positive. In contrast, approximately 90 percent of breast cancers in men express ER, and over 80 percent express PR [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/6,7,9,10,47,56,57\">",
"     6,7,9,10,47,56,57",
"    </a>",
"    ]. As in women with breast cancer, rates of hormone receptor positivity increase with age.",
"    <span class=\"nowrap\">",
"     ER/PR",
"    </span>",
"    expression may provide a growth advantage; some data suggest that in men, ER",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PR positive breast cancers have higher proliferative activity than do ER",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PR negative tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Androgen receptor (AR) expression is detected in 34 to 95 percent of breast cancers in men [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/56,58-60\">",
"     56,58-60",
"    </a>",
"    ]. However, no association between AR expression and other clinicopathologic features or measures of outcome has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/59\">",
"     59",
"    </a>",
"    ]. AR gene mutations, which are predominantly in the DNA-binding domain in an area responsible for transcriptional control, have been implicated in the development of MBC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. However, their contribution to tumorigenesis is not completely clear, and at least two separate series have failed to find any AR mutations in tumor material from 128 MBCs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     HER2 expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early data suggested similarities in the rate of expression of HER2 in breast cancers in men and those in women [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/56\">",
"     56",
"    </a>",
"    ]. However, more recent studies using standardized methodology have shown a lower rate of HER2 overexpression in men (2 to 15 percent in three different series [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]). Approximately 18 to 20 percent of female breast cancers overexpress HER2. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=see_link\">",
"     \"HER2 and predicting response to therapy in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HER2 expression should be assessed in all primary breast tumors in men as it is in women because of its predictive value. HER2 overexpression identifies patients who might benefit from treatment with HER2 targeted agents (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    ) both in the adjuvant and metastatic disease settings. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'HER2-directed agents'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H34\">",
"     'HER2-directed agents'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=see_link\">",
"     \"Measurement of prognostic factors in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancers in men typically presents as a painless, firm mass that is usually subareolar, less often in the upper outer quadrant [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/6,68\">",
"     6,68",
"    </a>",
"    ]. The left breast is involved slightly more often than the right, and fewer than one percent of cases are bilateral.",
"   </p>",
"   <p>",
"    Other findings at presentation include nipple retraction, ulceration of the nipple or skin, fixation to skin or underlying muscle, tumor tenderness, and palpable axillary nodes. The reported rate of nipple involvement is 40 to 50 percent, possibly because of the scarcity of breast tissue, and the central location of most tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/6,68\">",
"     6,68",
"    </a>",
"    ]. Serosanguinous or bloody nipple discharge is unusual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of a breast mass in a man includes gynecomastia, a breast abscess, metastases to the breast, and other non-breast cancer primary tumors (eg, sarcomas). In contrast to breast cancers in men, gynecomastia typically presents as bilateral symmetrical breast enlargement with poorly defined borders, no fixation to the underlying chest wall, and no axillary lymphadenopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/9/6294?source=see_link\">",
"     \"Epidemiology and pathogenesis of gynecomastia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION AND STAGING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mammography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the evaluation of a suspicious breast mass in a man is diagnostic imaging, usually including a mammogram and often ultrasound evaluation of the abnormality. The mammogram is abnormal in 80 to 90 percent of MBCs, and can usually distinguish between malignancy and gynecomastia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. In one study, the reported sensitivity and specificity rates of mammography for the diagnosis of MBC were 92 and 90 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic features suggestive of malignancy include eccentricity to the nipple, spiculated margins, and microcalcifications. In contrast, gynecomastia typically appears as a round or triangular area of increased density positioned symmetrically in the retroareolar region. In rare cases, concurrent gynecomastia can mask a malignant lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link\">",
"     \"Breast imaging: Mammography and ultrasonography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any suspicious mass requires biopsy to confirm the diagnosis and to assay for ER and PR content as well as HER2 status. Although fine needle aspiration (FNA) cytology can provide adequate diagnostic material in many cases, avoiding open or surgical biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/72-74\">",
"     72-74",
"    </a>",
"    ], up to one-fourth of samples are insufficient for diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/72\">",
"     72",
"    </a>",
"    ]. Compared to FNA, core needle biopsy offers a more definitive histologic diagnosis, avoids inadequate samples, and usually distinguishes between invasive versus in situ cancer. If inadequate tissue is obtained, an open biopsy should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link\">",
"     \"Breast biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Staging work-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation and staging system used for breast cancers in men are the same as for women with breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10009?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of newly diagnosed breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Breast cancer is classified according to a TNM staging system developed and maintained by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (IUCC) (",
"    <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/75\">",
"     75",
"    </a>",
"    ]. As in women, stage, tumor size and axillary lymph node status are the most important factors influencing outcome in breast cancers in men (see",
"    <a class=\"local\" href=\"#H36\">",
"     'Prognosis'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT FOR EARLY STAGE LOCALIZED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of localized invasive early stage breast cancer in men follows the same general principles as for female breast cancer. The primary tumor is usually treated surgically, with adjuvant systemic therapy administered in most cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Surgical resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional surgical approach for localized breast cancer in men is modified radical mastectomy (MRM). Although randomized studies have not been conducted in men, retrospective data suggest the equivalence of radical mastectomy and MRM in terms of local recurrence and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/7,76-78\">",
"     7,76-78",
"    </a>",
"    ]. Moreover, randomized studies in women also support the therapeutic equivalence of these two surgical procedures. The only exception is that men who have extensive chest wall muscle involvement may benefit from a radical mastectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=see_link&amp;anchor=H7005266#H7005266\">",
"     \"Mastectomy\", section on 'Types of mastectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Breast conserving therapy (partial mastectomy followed by breast irradiation) is also an option for men with breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/80\">",
"     80",
"    </a>",
"    ]. Although most men have a small volume of breast tissue, some men who develop breast cancer have sufficient breast tissue to permit breast conservation. In a review of data from the Surveillance, Epidemiology and End Results Program (SEER), 1541 cases of male breast cancer were identified and almost 20 percent were treated with breast conservation, despite the fact that men usually present with larger tumors than their female counterparts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/81\">",
"     81",
"    </a>",
"    ]. The SEER data does not include information on local recurrence rates, but in one retrospective study of seven men treated with breast conserving therapy with a median follow up of 67 months, there were no local recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link\">",
"     \"Breast conserving therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Men who want to avoid mastectomy and who have enough breast tissue so that adequate surgical margins can be obtained should be offered breast conserving surgery. However, men who opt for breast conserving surgery must also receive radiation therapy (RT). Data from the National Cancer Data Base on 4755 men with breast cancer showed that men treated with a partial mastectomy were less likely to receive appropriate postoperative RT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=see_link&amp;anchor=H8489445#H8489445\">",
"     \"Role of radiation therapy in breast conservation therapy\", section on 'Benefits'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Management of the regional nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical assessment of the axillary nodes is an essential part of primary therapy. Increasing amounts of data support the view that at least in women, surgical assessment of the axillary nodes is associated with a better outcome. In keeping with this conclusion, at least some data suggest that men who have nodal dissection omitted tend to have a worse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/7,83\">",
"     7,83",
"    </a>",
"    ]. The impact of ALND on survival in women with breast cancer is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=see_link&amp;anchor=H14#H14\">",
"     \"Management of the regional lymph nodes in breast cancer\", section on 'Impact of ALND on survival'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women with clinically node-negative breast cancer, sentinel lymph node (SLN) biopsy has emerged as a less morbid alternative to a full axillary node dissection. In experienced hands, the SLN accurately predicts the status of the remaining regional nodes, and a negative SLN eliminates the need for a complete axillary dissection. Individuals with a clinically suspicious axilla or biopsy-proven axillary nodal metastases are recommended to undergo axillary dissection.",
"   </p>",
"   <p>",
"    SLN biopsy may be successful in men as well, although the available data are scant. Due to the rarity of MBC, large studies establishing the sensitivity and specificity of SLN biopsy in MBC have not been carried out. However, in a total of 143 men reported in seven retrospective series, a SLN was successfully identified in all but one [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/84-89\">",
"     84-89",
"    </a>",
"    ]. A combined 11 men with a negative SLN biopsy underwent completion axillary node dissection, and none had additional involved nodes.",
"   </p>",
"   <p>",
"    Despite the limited amount of data, an expert panel convened by the American Society of Clinical Oncology (ASCO) concluded that the use of SLN biopsy for men with breast cancer was \"acceptable\" [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=see_link\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Adjuvant RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data regarding the indications for postmastectomy radiation therapy (RT) in men treated for breast cancer. In small retrospective series, postmastectomy RT appears to reduce locoregional recurrence in MBC, but the influence on survival is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/7,47,91-93\">",
"     7,47,91-93",
"    </a>",
"    ]. RT techniques vary substantially between series and over time, complicating the clinical assessment of benefit.",
"   </p>",
"   <p>",
"    For women with node-positive breast cancer, a survival advantage for postmastectomy chest wall irradiation has been shown in randomized trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=see_link&amp;anchor=H14#H14\">",
"     \"Postmastectomy chest wall irradiation\", section on 'Modern clinical trials'",
"    </a>",
"    .) Whether these results can be extrapolated to men is unclear, but at least one review from Johns Hopkins suggests that similar indications for postmastectomy RT should be applied to both men and women with breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/94\">",
"     94",
"    </a>",
"    ]. In fact, at least some data suggest that men are more likely to be offered postmastectomy RT than women, possibly because they have a higher incidence of nipple or skin involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with female breast cancer, postmastectomy RT is recommended for men with four or more positive lymph nodes",
"    <span class=\"nowrap\">",
"     (N2/N3",
"    </span>",
"    nodal disease), or locally advanced",
"    <span class=\"nowrap\">",
"     (T3/T4)",
"    </span>",
"    primary tumors (",
"    <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Treatment of locally advanced disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is far less agreement on patients (females or males) with fewer positive nodes, whose risk of locoregional relapse is lower. Given that node-positive breast cancer represents a continuum, it is difficult to conceive that a patient with three positive nodes would not be at high enough risk to justify treatment, whereas a patient with four positive nodes would qualify as high-risk. Data from a combined analysis of two Danish trials suggests that the survival benefit from postmastectomy RT is similar in patients with one to three, or four or more positive nodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=see_link&amp;anchor=H19#H19\">",
"     \"Postmastectomy chest wall irradiation\", section on 'Positive lymph nodes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional data to support benefit from RT in patients with fewer than four positive nodes comes from the NCIC CTG MA.20 trial, which demonstrated a significant locoregional and distant disease-free survival benefit (as well as a trend toward better overall survival) for the addition of locoregional irradiation to whole breast RT in women undergoing breast conserving therapy; 85 percent of enrolled patients had one to three positive lymph nodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=see_link&amp;anchor=H730200#H730200\">",
"     \"Role of radiation therapy in breast conservation therapy\", section on 'Benefits of regional nodal irradiation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These issues have led many to conclude that postmastectomy RT is an appropriate option for the majority of patients with node-positive breast cancer, but this is a controversial area and the recommendations from expert groups differ. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=see_link&amp;anchor=H9984477#H9984477\">",
"     \"Postmastectomy chest wall irradiation\", section on 'Guidelines from expert groups'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our view, all men with one to three positive nodes should be referred to a radiation oncologist for a thoughtful discussion of the benefits and risks of treatment so that they may make an informed decision. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=see_link&amp;anchor=H19#H19\">",
"     \"Postmastectomy chest wall irradiation\", section on 'Positive lymph nodes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant systemic therapy is recommended for the majority of men with breast cancer. The same guidelines for adjuvant systemic therapy in women with early stage breast cancer are generally followed for men who have breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H954223\">",
"    <span class=\"h3\">",
"     Endocrine therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H954644\">",
"    <span class=\"h4\">",
"     Tamoxifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the majority of breast cancers in men are hormone receptor-positive, adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    for at least five years is recommended for most men following local therapy. This recommendation is based largely upon the benefits that have been observed in clinical trials performed in women.",
"   </p>",
"   <p>",
"    On the basis of the Adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    : Longer Against Shorter (ATLAS) trial in women, which supported administration of ten rather than five years of tamoxifen, men with higher risk breast cancer based on tumor characteristics (eg, higher tumor grade, pathologic node involvement, and larger tumor size) and those who are tolerating treatment are appropriate candidates for extended tamoxifen treatment. For all others, a decision on whether to continue treatment beyond five years should be based on an individual consideration of their side effects (eg, hot flashes, sexual dysfunction). The results of the ATLAS trial are discussed separately. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Hormone receptors'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link&amp;anchor=H933462070#H933462070\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Tamoxifen'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Prospective trials to confirm the validity of this approach in men are not available. However, retrospective comparisons support a survival benefit from adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    in MBC [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/68,77,97-99\">",
"     68,77,97-99",
"    </a>",
"    ]. As an example, in one report, 39 men who received tamoxifen had better five year actuarial survival (61 versus 44 percent) and disease-free survival (56 versus 28 percent) compared with a group of historical controls who underwent mastectomy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the potential survival benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , several studies indicate that a large proportion of men discontinue treatment before five years, which may be associated with worse outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. In a study of 116 men, adherence rates fell from 65 percent at year 1 to 18 percent by year 5 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/101\">",
"     101",
"    </a>",
"    ]. Compared to men who were adherent to tamoxifen, low-adherence was associated with significantly lower rates of disease-free survival (42 versus 73 percent, respectively, p=0.007) and overall survival (50 versus 80 percent, p=0.008) at 10 years. Significant factors associated with low adherence included age &le;60 years (hazard ratio [HR] 1.10, 95% CI 1.01-1.21), lack of social support (HR 2.45, 95% CI 1.32-4.55), and adverse effects (HR 2.19, 95% CI 1.57-3.04). In this study, 64 percent experienced adverse events with the most common side effects being fatigue (21 percent), anxiety (20 percent), sleep disorders (19 percent), decreased libido (11 percent), and weight gain (10 percent).",
"   </p>",
"   <p>",
"    Based upon these results, interventions are needed to improve the adherence of men with breast cancer to complete the full five year treatment course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h4\">",
"     Aromatase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are insufficient data to support the use of an aromatase inhibitor in the adjuvant setting for breast cancers in men. The largest study to evaluate the use of an AI or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    was a retrospective analysis consisting of 257 men with stage I to III breast cancer who were treated with an AI (n= 50) or tamoxifen (n= 207) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/102\">",
"     102",
"    </a>",
"    ]. With a median follow-up of 42 months, treatment with an AI was associated with a higher risk of death during follow-up compared to tamoxifen (32 versus 18 percent had died, HR 1.55, 95% CI 1.13-2.13). Although the data are limited, they support the use of tamoxifen rather than an AI in the adjuvant setting for men with breast cancer. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , specific recommendations for adjuvant chemotherapy are based largely upon the benefits that have been observed in clinical trials performed in women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=see_link\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=see_link\">",
"     \"Adjuvant medical therapy for HER2-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prospective trials evaluating the benefits of adjuvant chemotherapy specifically for men with newly diagnosed breast cancer have not been performed. However, retrospective comparisons support a survival benefit from adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/47,83,103-106\">",
"     47,83,103-106",
"    </a>",
"    ]. As with women, systemic chemotherapy alone is appropriate for men with hormone receptor-negative, HER2-negative tumors that are &ge;1 cm and node negative, or node-positive of any size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     HER2-directed agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data regarding the benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    specifically in men with human epidermal growth factor 2 (HER2) positive breast cancer. However, as in women, treatment with HER2-directed therapy is indicated in men with HER2-positive breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=see_link\">",
"     \"Adjuvant medical therapy for HER2-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     TREATMENT OF LOCALLY ADVANCED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men who present with locally advanced (T3 or T4) or inflammatory breast cancer are treated similarly to women who present in this way. Induction chemotherapy is started initially, with surgery reserved for those whose tumors become operable. Postmastectomy RT is typically recommended in such cases, and adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    for hormone receptor-positive disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=see_link&amp;anchor=H528513711#H528513711\">",
"     \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\", section on 'Locally advanced breast cancer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31048?source=see_link\">",
"     \"Inflammatory breast cancer: Clinical features and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     TREATMENT OF ADVANCED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to men with metastatic or advanced breast cancer is similar to women with metastatic breast cancer. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Endocrine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with hormone receptor-positive breast cancer, hormone therapy is usually the first approach for men with metastatic breast cancer. Systemic chemotherapy is generally reserved for treatment of men with rapidly progressive or symptomatic visceral disease, those who become refractory to hormone therapy (ie, progress during or within 12 months of completion of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    treatment), and for the treatment of hormone receptor-negative tumors.",
"   </p>",
"   <p>",
"    Historically, endocrine therapy for men with breast cancer was ablative (ie, orchiectomy, adrenalectomy, hypophysectomy). The effectiveness of bilateral orchiectomy for advanced breast cancer in men was first reported in 1942 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/107\">",
"     107",
"    </a>",
"    ]; subsequent series indicate response rates between 32 and 67 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/6,108-111\">",
"     6,108-111",
"    </a>",
"    ]. However, due to the unwillingness of many men to accept orchiectomy or other surgical forms of therapy, medical (additive) hormone therapy has become the initial treatment of choice for advanced breast cancer.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    is the preferred initial agent. Over 80 percent of men with hormone receptor-positive advanced breast cancer respond to tamoxifen, but men with hormone nonresponsive (ie,",
"    <span class=\"nowrap\">",
"     ER/PR-negative)",
"    </span>",
"    disease do not benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/6,111-113\">",
"     6,111-113",
"    </a>",
"    ]. Other endocrine therapies (eg, aminoglutethimide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    , androgens, antiandrogens, corticosteroids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    , estrogens, luteinizing hormone-releasing hormone analogs) are associated with 50 to 70 percent response rates in ER-positive breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/112,114-116\">",
"     112,114-116",
"    </a>",
"    ]. However, side effect profiles tend to be less favorable than with tamoxifen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=see_link\">",
"     \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although they are very active in women with hormone-responsive advanced breast cancer, the utility of aromatase inhibitors (AIs) such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    in men is less clear. A few responses to aromatase inhibitors have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/117-120\">",
"     117-120",
"    </a>",
"    ]. In one retrospective series of 15 men with metastatic breast cancer who received an AI, there were two complete and four partial responses (response rate 40 percent); activity correlated with a significant reduction in estradiol levels [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any of these alternative endocrine therapies can be considered in men with ER-positive tumors who progress following treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , and who do not have rapidly progressive or life-threatening visceral disease. Men responding to one form of hormonal treatment have a greater likelihood of responding to subsequent hormonal manipulations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=see_link\">",
"     fulvestrant",
"    </a>",
"    is unclear. Two case reports totaling seven men documented a partial response in two and stable disease (in one case lasting 22 months) in three others [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/121,122\">",
"     121,122",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     HER2-directed agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are minimal data exploring the benefit of HER2-directed agents in advanced HER2-positive breast cancers in men. However, these agents should be administered for men with HER2-positive (3+ by immunohistochemistry or FISH-positive) breast cancer, either as monotherapy, or in combination with cytotoxic chemotherapy is reasonable in view of the strong evidence in support of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    in women with breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link&amp;anchor=H111523989#H111523989\">",
"     \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\", section on 'HER2-directed therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Cytotoxic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional cytotoxic chemotherapy is indicated for men with hormone-nonresponsive tumors, rapidly progressing or life-threatening visceral disease (because responses tend to occur more rapidly than with hormone therapy), and for those with initially hormone-responsive disease who become refractory to hormone therapy (ie, those who progress during endocrine therapy). These and other treatment principles are similar to those in women with advanced breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in women, tumor size and the presence as well as number of involved nodes are the most important prognostic factors for breast cancers in men [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/7,10,47,57,79,123-128\">",
"     7,10,47,57,79,123-128",
"    </a>",
"    ]. In two reports involving 335 and 397 cases of breast cancer in men respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/7,127\">",
"     7,127",
"    </a>",
"    ], ten-year disease-specific survival rates were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Histologically negative nodes &mdash; 77 and 84 percent",
"     </li>",
"     <li>",
"      One to three positive nodes &mdash; 50 and 44 percent",
"     </li>",
"     <li>",
"      Four or more histologically positive nodes &mdash; 24 and 14 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stratification of outcomes according to AJCC tumor stage can be illustrated by data derived from the SEER database, depicted in the following table (",
"    <a class=\"graphic graphic_table graphicRef60647 \" href=\"UTD.htm?21/54/22379\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Breast cancer in men has been considered an aggressive disease with a considerably worse prognosis than in women. However, the lower overall survival rates in some series have been attributed to older age and more advanced disease stage at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/10\">",
"     10",
"    </a>",
"    ]. Most contemporary reports of both male and female breast cancer that were carefully matched for age at diagnosis, stage and grade do not substantiate a significantly worse survival in men [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/2,10,81,82,128,130-132\">",
"     2,10,81,82,128,130-132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This absence of gender difference in contemporary series has been attributed by some to improvements in treatment of MBC. However, the data to support this hypothesis are conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 217 men treated between 1953 and 1995, men diagnosed after 1986 tended to present with earlier-stage disease and were more likely to be treated with modified radical mastectomy and adjuvant systemic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/47\">",
"       47",
"      </a>",
"      ]. Compared to earlier time periods, these differences coincided with improvements in five-year survival.",
"     </li>",
"     <li>",
"      Contrasting findings were noted in a separate report of 229 men treated between 1955 and 1996. Survival and other outcome measures did not appear to differ over time despite the increased use of standard primary surgical treatment and postoperative chemotherapy and endocrine therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Racial disparities",
"    </span>",
"    &nbsp;&mdash;&nbsp;As is the case in women, black men with breast cancer have a worse prognosis than do whites [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/5,133\">",
"     5,133",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link&amp;anchor=H8#H8\">",
"     \"Factors that modify breast cancer risk in women\", section on 'White race'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This was illustrated in a report of 510 men aged 65 years or older (456 white, 34 black) with stage I to III breast cancer derived from the linked",
"    <span class=\"nowrap\">",
"     Medicare/SEER",
"    </span>",
"    (Surveillance, Epidemiology and End Results) database [",
"    <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/133\">",
"     133",
"    </a>",
"    ]. Treatment consisted of mastectomy, chemotherapy, and radiation therapy in 94, 28, and 29 percent respectively.",
"   </p>",
"   <p>",
"    Compared to white men, blacks were significantly more likely to have advanced stage disease (eg, 24 versus 9 percent stage III) and larger tumor size. In addition, there was a nonsignificant trend for blacks to have more node-positive (45 versus 34 percent), and poorly differentiated tumors (44 versus 32 percent), fewer hormone receptor positive tumors (56 versus 72 percent), and comorbidity scores greater than 0 (53 versus 38 percent). Black men were approximately 50 percent less likely to be referred to a medical oncologist and to receive chemotherapy, but these differences were also not statistically significant. After adjusting for known clinical, demographic, and treatment-related factors, black men had a greater than threefold increased risk of dying as a result of their breast cancer compared to white men. Five year survival rates were 66 and 90 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Contralateral breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of a contralateral breast cancer appears to be higher for men than it is for women with breast cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 1788 men derived from the SEER database, 12 (0.7 percent) developed a contralateral breast cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/134\">",
"       134",
"      </a>",
"      ]. This represented a marked increase in relative risk compared to men who had not had breast cancer. Compared to the general population, the standardized incidence ratio (SIR) for contralateral breast cancer in male survivors was 30. However, for men diagnosed before 50 years the SIR was 110.",
"     </li>",
"     <li>",
"      Similar results were noted in a separate family cancer database series [",
"      <a class=\"abstract\" href=\"UTD.htm?25/36/26186/abstract/135\">",
"       135",
"      </a>",
"      ]. Men with a history of breast cancer had a 93-fold higher risk of developing contralateral breast cancer than men without such a history. The absolute risk for an individual man with breast cancer developing a contralateral breast cancer was 1.75 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the significantly increased risk of a contralateral cancer in men with a history of breast cancer, the absolute risk of a contralateral breast cancer is much greater in women because of the higher prevalence of the disease. The role of screening mammography for the contralateral breast in men with MBC has not been explored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=see_link\">",
"       \"Patient information: Breast cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/11/27827?source=see_link\">",
"       \"Patient information: Treatment of metastatic breast cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5239419\">",
"    <span class=\"h2\">",
"     Clinical presentation and evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breast cancer is much less common in men than in women. Men tend to present at an older age than women. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Furthermore, invasive ductal breast cancers predominate in men (&ge;90 percent), while ductal in situ (DCIS) is less common, and lobular cancers are rare. Breast cancers that arise in men are more often hormone receptor positive than female breast cancers, but they less often overexpress HER2. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Histologic, biologic, and molecular features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common clinical presentation is a painless, firm, subareolar mass. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical features'",
"      </a>",
"      above.) Mammography is abnormal in 80 to 90 percent of cases, and can usually differentiate breast cancer from gynecomastia. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biopsy is required to confirm the diagnosis and assay for hormone receptors and HER2 expression, both of which may influence the selection of treatment. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnostic evaluation and staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The staging workup and TNM staging system for MBC is identical to that used for female breast cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10009?source=see_link\">",
"       \"Clinical features, diagnosis, and staging of newly diagnosed breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Any man with a diagnosis of breast cancer should be referred for genetic counseling and BRCA testing. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, treatment for men parallels that for women with breast cancer, with certain exceptions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For surgical treatment of male breast cancer, we recommend simple mastectomy rather than more radical surgery (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For men who prefer breast conservation and have adequate breast tissue to ensure negative margins, we suggest breast conserving therapy rather than mastectomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Men who opt for breast conserving surgery must also receive radiation therapy. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Surgical resection'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      More extensive surgery may be needed if invasion of the chest wall musculature is found at the time of surgery. However, if T3 disease is suspected at the time of initial evaluation, an approach that utilizes initial chemotherapy followed by surgery is preferred. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Treatment of locally advanced disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As in women, surgical evaluation of the axillary lymph nodes is needed to guide adjuvant therapy (both radiation therapy and systemic therapy). An expert panel convened by the American Society of Clinical Oncology (ASCO) considered sentinel lymph node (SLN) biopsy to be an acceptable alternative to full axillary node dissection for men with breast cancer and a clinically negative axilla. We suggest SLN biopsy instead of full axillary node dissection in institutions where surgical expertise is available (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For men with clinically suspicious or histologically confirmed positive axillary nodes, or a positive SLN biopsy, we suggest full axillary dissection (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Management of the regional nodes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As in women, we recommend postoperative chest wall and regional lymph node irradiation following mastectomy in men who are at high risk of relapse because of four or more involved axillary lymph nodes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      locally advanced (T3 or T4) disease (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Men with one to three positive lymph nodes should be referred to a radiation oncologist for a discussion of the risks and benefits of postmastectomy chest wall irradiation. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Adjuvant RT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with newly diagnosed breast cancer, we recommend adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      rather than an aromatase inhibitor or observation&nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H954223\">",
"       'Endocrine therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend adjuvant chemotherapy for all men with hormone receptor-negative tumors &ge;1 cm or with axillary nodal metastases, regardless of tumor size (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For men with hormone receptor-positive breast cancer, we recommend adjuvant chemotherapy (in addition to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      ) in the presence of axillary nodal metastases, regardless of tumor size (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For men with hormone receptor-positive, node-negative disease, we use the results of the 21-gene recurrence score assay to predict the risk of recurrence and identify those who are likely to benefit from chemotherapy added to adjuvant endocrine therapy. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Chemotherapy'",
"      </a>",
"      above.) If combined",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      and chemotherapy are indicated, we recommend that tamoxifen be administered sequentially after the completion of chemotherapy and not concurrently (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"       \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The same chemotherapy regimens as are used in the treatment of women with early stage breast cancer are appropriate choices for men as well. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=see_link\">",
"       \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest incorporation of a HER2-directed agent in men with HER2-positive breast cancer (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Adjuvant therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with locally advanced (T3 or T4) or inflammatory breast cancer, we suggest administration of primary chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Surgery should be reserved for those whose tumors become operable. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=see_link&amp;anchor=H528513711#H528513711\">",
"       \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\", section on 'Locally advanced breast cancer'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31048?source=see_link\">",
"       \"Inflammatory breast cancer: Clinical features and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For men with metastatic breast cancer, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      if the tumor is hormone responsive&nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). However, we recommend initial chemotherapy rather than hormone therapy for men with rapidly progressing or life-threatening visceral disease, those who progress on or within 12 months of prior endocrine therapy, and for men with hormone receptor-negative advanced disease (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend incorporation of a HER2-directed agent to treatment for men with HER2-positive advanced breast cancer (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Treatment of advanced disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/1\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/2\">",
"      Anderson WF, Althuis MD, Brinton LA, Devesa SS. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 2004; 83:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/3\">",
"      Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer 1993; 53:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/4\">",
"      Thomas DB. Breast cancer in men. Epidemiol Rev 1993; 15:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/5\">",
"      O'Malley CD, Prehn AW, Shema SJ, Glaser SL. Racial/ethnic differences in survival rates in a population-based series of men with breast carcinoma. Cancer 2002; 94:2836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/6\">",
"      Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002; 137:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/7\">",
"      Cutuli B, Lacroze M, Dilhuydy JM, et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer 1995; 31A:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/8\">",
"      Mabuchi K, Bross DS, Kessler II. Risk factors for male breast cancer. J Natl Cancer Inst 1985; 74:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/9\">",
"      Nahleh ZA, Srikantiah R, Safa M, et al. Male breast cancer in the veterans affairs population: a comparative analysis. Cancer 2007; 109:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/10\">",
"      Giordano SH, Cohen DS, Buzdar AU, et al. Breast carcinoma in men: a population-based study. Cancer 2004; 101:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/11\">",
"      Brinton LA, Richesson DA, Gierach GL, et al. Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst 2008; 100:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/12\">",
"      Thomas DB, Jimenez LM, McTiernan A, et al. Breast cancer in men: risk factors with hormonal implications. Am J Epidemiol 1992; 135:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/13\">",
"      Lenfant-Pejovic MH, Mlika-Cabanne N, Bouchardy C, Auquier A. Risk factors for male breast cancer: a Franco-Swiss case-control study. Int J Cancer 1990; 45:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/14\">",
"      Misra SP, Misra V, Dwivedi M. Cancer of the breast in a male cirrhotic: is there an association between the two? Am J Gastroenterol 1996; 91:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/15\">",
"      S&oslash;rensen HT, Friis S, Olsen JH, et al. Risk of breast cancer in men with liver cirrhosis. Am J Gastroenterol 1998; 93:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/16\">",
"      EL-GAZAYERLI MM, ABDEL-AZIZ AS. ON BILHARZIASIS AND MALE BREAST CANCER IN EGYPT: A PRELIMINARY REPORT AND REVIEW OF THE LITERATURE. Br J Cancer 1963; 17:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/17\">",
"      Bhagwandeen SB. Carcinoma of the male breast in Zambia. East Afr Med J 1972; 49:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/18\">",
"      Harnden DG, Maclean N, Langlands AO. Carcinoma of the breast and Klinefelter's syndrome. J Med Genet 1971; 8:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/19\">",
"      Scheike O, Visfeldt J, Petersen B. Male breast cancer. 3. Breast carcinoma in association with the Klinefelter syndrome. Acta Pathol Microbiol Scand A 1973; 81:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/20\">",
"      Hultborn R, Hanson C, K&ouml;pf I, et al. Prevalence of Klinefelter's syndrome in male breast cancer patients. Anticancer Res 1997; 17:4293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/21\">",
"      Brinton LA. Breast cancer risk among patients with Klinefelter syndrome. Acta Paediatr 2011; 100:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/22\">",
"      Gordon GG, Olivo J, Rafil F, Southren AL. Conversion of androgens to estrogens in cirrhosis of the liver. J Clin Endocrinol Metab 1975; 40:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/23\">",
"      Olsson H, Alm P, Aspegren K, et al. Increased plasma prolactin levels in a group of men with breast cancer--a preliminary study. Anticancer Res 1990; 10:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/24\">",
"      Volm MD, Talamonti MS, Thangavelu M, Gradishar WK. Pituitary adenoma and bilateral male breast cancer: an unusual association. J Surg Oncol 1997; 64:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/25\">",
"      Ballerini P, Recchione C, Cavalleri A, et al. Hormones in male breast cancer. Tumori 1990; 76:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/26\">",
"      Hogervorst FB, Cornelis RS, Bout M, et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 1995; 10:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/27\">",
"      Struewing JP, Brody LC, Erdos MR, et al. Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet 1995; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/28\">",
"      Ottini L, Masala G, D'Amico C, et al. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res 2003; 63:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/29\">",
"      Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004; 22:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/30\">",
"      Machado PM, Brand&atilde;o RD, Cavaco BM, et al. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 2007; 25:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/31\">",
"      Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2007; 99:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/32\">",
"      Easton DF, Steele L, Fields P, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997; 61:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/33\">",
"      Couch FJ, Farid LM, DeShano ML, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996; 13:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/34\">",
"      Thorlacius S, Sigurdsson S, Bjarnadottir H, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 1997; 60:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/35\">",
"      Csokay B, Udvarhelyi N, Sulyok Z, et al. High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res 1999; 59:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/36\">",
"      Friedman LS, Gayther SA, Kurosaki T, et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997; 60:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/37\">",
"      Mavraki E, Gray IC, Bishop DT, Spurr NK. Germline BRCA2 mutations in men with breast cancer. Br J Cancer 1997; 76:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/38\">",
"      Haraldsson K, Loman N, Zhang QX, et al. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 1998; 58:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/39\">",
"      D&iacute;ez O, Cort&eacute;s J, Dom&egrave;nech M, et al. BRCA2 germ-line mutations in Spanish male breast cancer patients. Ann Oncol 2000; 11:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/40\">",
"      Domchek SM, Eisen A, Calzone K, et al. Application of breast cancer risk prediction models in clinical practice. J Clin Oncol 2003; 21:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/41\">",
"      Sverdlov RS, Barshack I, Bar Sade RB, et al. Genetic analyses of male breast cancer in Israel. Genet Test 2000; 4:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/42\">",
"      Basham VM, Lipscombe JM, Ward JM, et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 2002; 4:R2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/43\">",
"      Ding YC, Steele L, Kuan CJ, et al. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat 2011; 126:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/44\">",
"      Silvestri V, Rizzolo P, Zanna I, et al. PALB2 mutations in male breast cancer: a population-based study in Central Italy. Breast Cancer Res Treat 2010; 122:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/45\">",
"      Boyd J, Rhei E, Federici MG, et al. Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. Breast Cancer Res Treat 1999; 53:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/46\">",
"      Willsher PC, Leach IH, Ellis IO, et al. Male breast cancer: pathological and immunohistochemical features. Anticancer Res 1997; 17:2335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/47\">",
"      Donegan WL, Redlich PN, Lang PJ, Gall MT. Carcinoma of the breast in males: a multiinstitutional survey. Cancer 1998; 83:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/48\">",
"      Ciatto S, Iossa A, Bonardi R, Pacini P. Male breast carcinoma: review of a multicenter series of 150 cases. Coordinating Center and Writing Committee of FONCAM (National Task Force for Breast Cancer), Italy. Tumori 1990; 76:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/49\">",
"      Michaels BM, Nunn CR, Roses DF. Lobular carcinoma of the male breast. Surgery 1994; 115:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/50\">",
"      Camus MG, Joshi MG, Mackarem G, et al. Ductal carcinoma in situ of the male breast. Cancer 1994; 74:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/51\">",
"      Anderson WF, Devesa SS. In situ male breast carcinoma in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute. Cancer 2005; 104:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/52\">",
"      Hittmair AP, Lininger RA, Tavassoli FA. Ductal carcinoma in situ (DCIS) in the male breast: a morphologic study of 84 cases of pure DCIS and 30 cases of DCIS associated with invasive carcinoma--a preliminary report. Cancer 1998; 83:2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/53\">",
"      Desai DC, Brennan EJ Jr, Carp NZ. Paget's disease of the male breast. Am Surg 1996; 62:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/54\">",
"      Takeuchi T, Komatsuzaki M, Minesaki Y, et al. Paget's disease arising near a male areola without an underlying carcinoma. J Dermatol 1999; 26:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/55\">",
"      Spigel JJ, Evans WP, Grant MD, et al. Male inflammatory breast cancer. Clin Breast Cancer 2001; 2:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/56\">",
"      Rayson D, Erlichman C, Suman VJ, et al. Molecular markers in male breast carcinoma. Cancer 1998; 83:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/57\">",
"      Joshi MG, Lee AK, Loda M, et al. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer 1996; 77:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/58\">",
"      Mu&ntilde;oz de Toro MM, Maffini MV, Kass L, Luque EH. Proliferative activity and steroid hormone receptor status in male breast carcinoma. J Steroid Biochem Mol Biol 1998; 67:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/59\">",
"      Pich A, Margaria E, Chiusa L, et al. Androgen receptor expression in male breast carcinoma: lack of clinicopathological association. Br J Cancer 1999; 79:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/60\">",
"      Bezwoda WR, Hesdorffer C, Dansey R, et al. Breast cancer in men. Clinical features, hormone receptor status, and response to therapy. Cancer 1987; 60:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/61\">",
"      Wooster R, Mangion J, Eeles R, et al. A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat Genet 1992; 2:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/62\">",
"      Lobaccaro JM, Lumbroso S, Belon C, et al. Androgen receptor gene mutation in male breast cancer. Hum Mol Genet 1993; 2:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/63\">",
"      Hiort O, Naber SP, Lehners A, et al. The role of androgen receptor gene mutations in male breast carcinoma. J Clin Endocrinol Metab 1996; 81:3404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/64\">",
"      Syrj&auml;koski K, Hyytinen ER, Kuukasj&auml;rvi T, et al. Androgen receptor gene alterations in Finnish male breast cancer. Breast Cancer Res Treat 2003; 77:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/65\">",
"      Rudlowski C, Friedrichs N, Faridi A, et al. Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 2004; 84:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/66\">",
"      Bloom KJ, Govil H, Gattuso P, et al. Status of HER-2 in male and female breast carcinoma. Am J Surg 2001; 182:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/67\">",
"      Muir D, Kanthan R, Kanthan SC. Male versus female breast cancers. A population-based comparative immunohistochemical analysis. Arch Pathol Lab Med 2003; 127:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/68\">",
"      Goss PE, Reid C, Pintilie M, et al. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer 1999; 85:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/69\">",
"      Evans GF, Anthony T, Turnage RH, et al. The diagnostic accuracy of mammography in the evaluation of male breast disease. Am J Surg 2001; 181:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/70\">",
"      Dershaw DD, Borgen PI, Deutch BM, Liberman L. Mammographic findings in men with breast cancer. AJR Am J Roentgenol 1993; 160:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/71\">",
"      Appelbaum AH, Evans GF, Levy KR, et al. Mammographic appearances of male breast disease. Radiographics 1999; 19:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/72\">",
"      Joshi A, Kapila K, Verma K. Fine needle aspiration cytology in the management of male breast masses. Nineteen years of experience. Acta Cytol 1999; 43:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/73\">",
"      Westenend PJ, Jobse C. Evaluation of fine-needle aspiration cytology of breast masses in males. Cancer 2002; 96:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/74\">",
"      Vetto J, Schmidt W, Pommier R, et al. Accurate and cost-effective evaluation of breast masses in males. Am J Surg 1998; 175:383.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/76\">",
"      Ouriel K, Lotze MT, Hinshaw JR. Prognostic factors of carcinoma of the male breast. Surg Gynecol Obstet 1984; 159:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/77\">",
"      Digenis AG, Ross CB, Morrison JG, et al. Carcinoma of the male breast: a review of 41 cases. South Med J 1990; 83:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/78\">",
"      Gough DB, Donohue JH, Evans MM, et al. A 50-year experience of male breast cancer: is outcome changing? Surg Oncol 1993; 2:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/79\">",
"      Borgen PI, Wong GY, Vlamis V, et al. Current management of male breast cancer. A review of 104 cases. Ann Surg 1992; 215:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/80\">",
"      Golshan M, Rusby J, Dominguez F, Smith BL. Breast conservation for male breast carcinoma. Breast 2007; 16:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/81\">",
"      Gnerlich JL, Deshpande AD, Jeffe DB, et al. Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration. Ann Surg Oncol 2011; 18:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/82\">",
"      Scott-Conner CE, Jochimsen PR, Menck HR, Winchester DJ. An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery 1999; 126:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/83\">",
"      Yildirim E, Berberolu U. Male breast cancer: a 22-year experience. Eur J Surg Oncol 1998; 24:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/84\">",
"      Port ER, Fey JV, Cody HS 3rd, Borgen PI. Sentinel lymph node biopsy in patients with male breast carcinoma. Cancer 2001; 91:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/85\">",
"      Cimmino VM, Degnim AC, Sabel MS, et al. Efficacy of sentinel lymph node biopsy in male breast cancer. J Surg Oncol 2004; 86:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/86\">",
"      Goyal A, Horgan K, Kissin M, et al. Sentinel lymph node biopsy in male breast cancer patients. Eur J Surg Oncol 2004; 30:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/87\">",
"      De Cicco C, Baio SM, Veronesi P, et al. Sentinel node biopsy in male breast cancer. Nucl Med Commun 2004; 25:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/88\">",
"      Gentilini O, Chagas E, Zurrida S, et al. Sentinel lymph node biopsy in male patients with early breast cancer. Oncologist 2007; 12:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/89\">",
"      Boughey JC, Bedrosian I, Meric-Bernstam F, et al. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg 2006; 203:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/90\">",
"      Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23:7703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/91\">",
"      Spence RA, MacKenzie G, Anderson JR, et al. Long-term survival following cancer of the male breast in Northern Ireland. A report of 81 cases. Cancer 1985; 55:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/92\">",
"      Erlichman C, Murphy KC, Elhakim T. Male breast cancer: a 13-year review of 89 patients. J Clin Oncol 1984; 2:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/93\">",
"      Schuchardt U, Seegenschmiedt MH, Kirschner MJ, et al. Adjuvant radiotherapy for breast carcinoma in men: a 20-year clinical experience. Am J Clin Oncol 1996; 19:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/94\">",
"      Chakravarthy A, Kim CR. Post-mastectomy radiation in male breast cancer. Radiother Oncol 2002; 65:99.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/96\">",
"      Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist 2005; 10:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/97\">",
"      Ribeiro G, Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 1992; 65:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/98\">",
"      Ribeiro G, Swindell R, Harris M, et al. A review of the management of male breast carcinoma based on an analysis of 420 treated cases. Breast 1996; 5:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/99\">",
"      Giordano SH, Perkins GH, Broglio K, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer 2005; 104:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/100\">",
"      Anelli TF, Anelli A, Tran KN, et al. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 1994; 74:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/101\">",
"      Xu S, Yang Y, Tao W, et al. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Res Treat 2012; 136:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/102\">",
"      Eggemann H, Ignatov A, Smith BJ, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat 2013; 137:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/103\">",
"      Wang-Rodriguez J, Cross K, Gallagher S, et al. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol 2002; 15:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/104\">",
"      Patel HZ 2nd, Buzdar AU, Hortobagyi GN. Role of adjuvant chemotherapy in male breast cancer. Cancer 1989; 64:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/105\">",
"      Bagley CS, Wesley MN, Young RC, Lippman ME. Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol 1987; 10:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/106\">",
"      Izquierdo MA, Alonso C, De Andres L, Ojeda B. Male breast cancer. Report of a series of 50 cases. Acta Oncol 1994; 33:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/107\">",
"      Farrow JH, Adair FE. EFFECT OF ORCHIDECTOMY ON SKELETAL METASTASES FROM CANCER OF THE MALE BREAST. Science 1942; 95:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/108\">",
"      Stierer M, Rosen H, Weitensfelder W, et al. Male breast cancer: Austrian experience. World J Surg 1995; 19:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/109\">",
"      Kraybill WG, Kaufman R, Kinne D. Treatment of advanced male breast cancer. Cancer 1981; 47:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/110\">",
"      Patel JK, Nemoto T, Dao TL. Metastatic breast cancer in males. Assessment of endocrine therapy. Cancer 1984; 53:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/111\">",
"      Kantarjian H, Yap HY, Hortobagyi G, et al. Hormonal therapy for metastatic male breast cancer. Arch Intern Med 1983; 143:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/112\">",
"      Jaiyesimi IA, Buzdar AU, Sahin AA, Ross MA. Carcinoma of the male breast. Ann Intern Med 1992; 117:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/113\">",
"      Lopez M, Di Lauro L, Lazzaro B, Papaldo P. Hormonal treatment of disseminated male breast cancer. Oncology 1985; 42:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/114\">",
"      Labrie F, Dupont A, B&eacute;langer A, et al. Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report. Clin Invest Med 1990; 13:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/115\">",
"      Lopez M, Natali M, Di Lauro L, et al. Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. Cancer 1993; 72:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/116\">",
"      Doberauer C, Niederle N, Schmidt CG. Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide. Cancer 1988; 62:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/117\">",
"      Zabolotny BP, Zalai CV, Meterissian SH. Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol 2005; 90:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/118\">",
"      Italiano A, Largillier R, Marcy PY, et al. [Complete remission obtained with letrozole in a man with metastatic breast cancer]. Rev Med Interne 2004; 25:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/119\">",
"      Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 2002; 25:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/120\">",
"      Doyen J, Italiano A, Largillier R, et al. Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol 2010; 21:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/121\">",
"      Agrawal A, Cheung KL, Robertson JF. Fulvestrant in advanced male breast cancer. Breast Cancer Res Treat 2007; 101:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/122\">",
"      Masci G, Gandini C, Zuradelli M, et al. Fulvestrant for advanced male breast cancer patients: a case series. Ann Oncol 2011; 22:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/123\">",
"      Yap HY, Tashima CK, Blumenschein GR, Eckles NE. Male breast cancer: a natural history study. Cancer 1979; 44:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/124\">",
"      Salvadori B, Saccozzi R, Manzari A, et al. Prognosis of breast cancer in males: an analysis of 170 cases. Eur J Cancer 1994; 30A:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/125\">",
"      Vetto J, Jun SY, Paduch D, et al. Stages at presentation, prognostic factors, and outcome of breast cancer in males. Am J Surg 1999; 177:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/126\">",
"      Williams WL Jr, Powers M, Wagman LD. Cancer of the male breast: a review. J Natl Med Assoc 1996; 88:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/127\">",
"      Guinee VF, Olsson H, Moller T, et al. The prognosis of breast cancer in males. A report of 335 cases. Cancer 1993; 71:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/128\">",
"      Herman K, Lobaziewicz W, Skotnicki P, et al. Male breast cancer. Does the prognosis differ compared to female? Neoplasma 2000; 47:191.",
"     </a>",
"    </li>",
"    <li>",
"     Surveillance, Epidemiology and End Results (SEER) program www.seer.cancer.gov (Accessed on June 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/130\">",
"      Borgen PI, Senie RT, McKinnon WM, Rosen PP. Carcinoma of the male breast: analysis of prognosis compared with matched female patients. Ann Surg Oncol 1997; 4:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/131\">",
"      Willsher PC, Leach IH, Ellis IO, et al. A comparison outcome of male breast cancer with female breast cancer. Am J Surg 1997; 173:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/132\">",
"      El-Tamer MB, Komenaka IK, Troxel A, et al. Men with breast cancer have better disease-specific survival than women. Arch Surg 2004; 139:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/133\">",
"      Crew KD, Neugut AI, Wang X, et al. Racial disparities in treatment and survival of male breast cancer. J Clin Oncol 2007; 25:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/134\">",
"      Auvinen A, Curtis RE, Ron E. Risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst 2002; 94:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/36/26186/abstract/135\">",
"      Dong C, Hemminki K. Second primary breast cancer in men. Breast Cancer Res Treat 2001; 66:171.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 779 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-7920B88E07-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_36_26186=[""].join("\n");
var outline_f25_36_26186=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H41\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Inherited conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HISTOLOGIC, BIOLOGIC, AND MOLECULAR FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hormone receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HER2 expression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSTIC EVALUATION AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mammography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Staging work-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT FOR EARLY STAGE LOCALIZED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Surgical resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Management of the regional nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Adjuvant RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H954223\">",
"      - Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H954644\">",
"      Tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - HER2-directed agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      TREATMENT OF LOCALLY ADVANCED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      TREATMENT OF ADVANCED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      HER2-directed agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Cytotoxic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Racial disparities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Contralateral breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5239419\">",
"      Clinical presentation and evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/779\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/779|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/35/21053\" title=\"table 1\">",
"      Drugs and gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/5/31836\" title=\"table 2\">",
"      BRCA2 mutations male breast CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/58/22445\" title=\"table 3\">",
"      BRCA testing NCCN criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/14/29920\" title=\"table 4\">",
"      TNM stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/54/22379\" title=\"table 5\">",
"      Outcomes of Rx male breast Ca",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=related_link\">",
"      Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=related_link\">",
"      Adjuvant medical therapy for HER2-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=related_link\">",
"      Breast biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=related_link\">",
"      Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=related_link\">",
"      Breast imaging: Mammography and ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27384?source=related_link\">",
"      Causes and evaluation of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=related_link\">",
"      Causes of primary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10009?source=related_link\">",
"      Clinical features, diagnosis, and staging of newly diagnosed breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/9/6294?source=related_link\">",
"      Epidemiology and pathogenesis of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5064?source=related_link\">",
"      Genetic risk assessment for individuals at risk for hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=related_link\">",
"      HER2 and predicting response to therapy in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31048?source=related_link\">",
"      Inflammatory breast cancer: Clinical features and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=related_link\">",
"      Li-Fraumeni syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=related_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=related_link\">",
"      Management of the regional lymph nodes in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=related_link\">",
"      Mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=related_link\">",
"      Measurement of prognostic factors in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=related_link\">",
"      PTEN hamartoma tumor syndrome, including Cowden syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/14?source=related_link\">",
"      Paget disease of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16040?source=related_link\">",
"      Pathology of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=related_link\">",
"      Patient information: Breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/11/27827?source=related_link\">",
"      Patient information: Treatment of metastatic breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=related_link\">",
"      Postmastectomy chest wall irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31562?source=related_link\">",
"      Risk factors for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=related_link\">",
"      Role of radiation therapy in breast conservation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Molecular targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=related_link\">",
"      Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_36_26187="Classification organic acidemia";
var content_f25_36_26187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of organic acidemias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Branched-chain organic acidemias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methylmalonic aciduria and related disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propionic acidemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isovaleric aciduria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3-Methylcrotonylglycinuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3-Methylglutaconic aciduria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3-Hydroxyisobutyric aciduria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Multiple carboxylase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Holocarboxylase synthetase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biotinidase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Glutaric aciduria type I and related conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glutaric aciduria type I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        L-2-Hydroxyglutaric aciduria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mevalonic aciduria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Fatty acid oxidation defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disorders of energy metabolism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_36_26187=[""].join("\n");
var outline_f25_36_26187=null;
var title_f25_36_26188="Pregnancy outcome after assault";
var content_f25_36_26188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Outcome in women assaulted during pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"       </td>",
"       <td class=\"subtitle1\">",
"        Untraumatized controls, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Delivery during hospitalization for assault, percent&bull; (N=269)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Delivery subsequent to hospitalization for assault, percent (N=1801)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Maternal outcome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Preterm labor",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"       <td>",
"        16.4&Delta;",
"       </td>",
"       <td>",
"        10.5&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abruption",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"       <td>",
"        5.4&Delta;",
"       </td>",
"       <td>",
"        2.1&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Death",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        0.7&Delta;",
"       </td>",
"       <td>",
"        0.17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Uterine rupture*",
"       </td>",
"       <td>",
"        0.01-0.07",
"       </td>",
"       <td>",
"        0.7&Delta;",
"       </td>",
"       <td>",
"        0.11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Infant outcome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Preterm delivery",
"       </td>",
"       <td>",
"        9.7",
"       </td>",
"       <td>",
"        23.9&Delta;",
"       </td>",
"       <td>",
"        15.2&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Low birth weight",
"       </td>",
"       <td>",
"        5.8",
"       </td>",
"       <td>",
"        27.1&Delta;",
"       </td>",
"       <td>",
"        13.4&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asphyxia",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        1.4&Delta;",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fetal death",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        9.3&Delta;",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neonatal death",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"       <td>",
"        7.5&Delta;",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infant death",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"       <td>",
"        8.2&Delta;",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Range indicates before labor and during labor.",
"     <br>",
"      &bull; All values significantly different from controls.",
"      <br>",
"       &Delta; Values significantly different from controls.",
"       <br>",
"        PROM: premature rupture of membranes; RDS: respiratory distress syndrome.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: El Kady, D, Gilbert, WM, Xing, G, Smith, LH. Obstet Gynecol 2005; 105:357.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_36_26188=[""].join("\n");
var outline_f25_36_26188=null;
var title_f25_36_26189="Insulin benefit in NOD mouse";
var content_f25_36_26189=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F81644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F81644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Insulin prevents diabetes in NOD mouse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 245px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of immunization with intact insulin, the A or B chain of insulin, or diluent on the development of diabetes in the NOD mouse. Both intact insulin and the B chain were protective.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Muir A, Peck A, Clare-Salzler M, et al. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription.&nbsp;J Clin Invest 1995; 95:628.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_36_26189=[""].join("\n");
var outline_f25_36_26189=null;
var title_f25_36_26190="Intracranial compensation for mass";
var content_f25_36_26190=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intracranial compensation for an expanding mass lesion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 413px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Pathophysiology and management of the intracranial vault. In: Textbook of Pediatric Intensive Care, 3rd ed, Rogers, MC (Ed), Williams and Wilkins 1996. p. 646; figure 18.1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_36_26190=[""].join("\n");
var outline_f25_36_26190=null;
var title_f25_36_26191="Felon cross section";
var content_f25_36_26191=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cross section of felon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The fingertip pulp contains compartments of eccrine sweat glands and fat globules separated by fibrous septae. An abscess within these compartments is a felon. The locations of the neurovascular bundles are shown; these areas should be avoided when incision and drainage are performed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Clark, DC. Common acute hand infections. Am Fam Physician 2003; 68:2167.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_36_26191=[""].join("\n");
var outline_f25_36_26191=null;
